 A Randomized Phase 2 Pilot Study of Type I-Polarized Autologous Dendritic Cell Vaccines 
Incorporating Tumor Blood Vessel Antigen (TBVA)-Derived Peptides in Combination with 
Dasatinib in Patients with Metastatic Melanoma  
 
UPCI Protocol #: 12-048 
BB-IND#: 15,224 
Phase: 2 
V
ersion: 10 
Version Date: 07-14-17 
Investigational Agents: Alpha-type-1 Dendritic Cell Vaccine 
Dasatinib (NSC-732517) 
 
SPONSOR:  Walter J. Storkus, PhD 
Professor of Dermatology and Immunology 
W1041.2 Biomedical Sciences Tower 
University of Pittsburgh School of Medicine 
200 Lothrop Street 
Pittsburgh, PA 15213 
Tel: 412-648-9981 
Fax: 412-383-5857 
Email: storkuswj@upmc.edu  
 
PRINCIPAL INVESTIGATOR:  John Kirkwood, MD 
5115 Centre Avenue 
Pittsburgh, PA  15232 
Tel: 412-623-7707 
Fax: 412-648-6650 
E-mail: kirkwoodjm@upmc.edu 
 
Biostatistician : Yan Lin, PhD 
Research Assistant Professor 
Department of Biostatistics, Graduate School of Public Health 
University of Pittsburgh and Biostatistics Facility 
University of Pittsburgh Cancer Institute 
Sterling Plaza, Suite 325 
201 North Craig Street 
Pittsburgh, PA 15213 
Tel: 412-383-1311 
Fax: 412-383-1535 
Email: yal14@pitt.edu 
 
Immunologic Monitoring and 
Cellular Products Laboratory:  Lisa H. Butterfield, PhD, Director 
Associate Professor of Medicine, Surgery and Immunology 
Director, UPCI Immunologic Monitoring and Cellular Products 
Laboratory  
Hillman Cancer Center 
5117 Centre Avenue, Suite 1.27 
Pittsburgh, PA  15213 
 
  
Source(s) of Support : BMS 
 
Study Monitor : Education and Compliance Office for Human Subject Research 
Research Conduct and Compliance Office 
University of Pittsburgh 
3500 Fifth Avenue, Suite 205 
Pittsburgh, PA 15213 
SCHEMA 
 
 
 

TABLE OF CONTENTS 
SCHEMA ..................................................................................................................................................... 3 
LIST OF ABBREVIATIONS .................................................................................................................... 7 
1. OBJECTIVES .................................................................................................................................. 1 
1.1 Pri
mary Objectives .................................................................................................................... 1 
1.2 Secondary Objectives ................................................................................................................ 1 
2. BACKGROUND ............................................................................................................................. 1 
2.1 Melanoma .................................................................................................................................. 1 
2.2 Dasatinib .................................................................................................................................... 2 
2.2.1  Preclinical Anti-tumor Activity .........................................................................................................2  
2.2.1.1  In Vitro Molecular Studies ................................................................................................  2 
2.2.1.2  Cellular Studies .................................................................................................................. 3  
2.2.1.3  In Vivo Studies .................................................................................................................. 3  
2.2.1.4  Preclinical Toxicology ....................................................................................................... 3  
2.2.2  Clinical Pharmacokinetics .................................................................................................................3  
2.2.2.1  Absorption ......................................................................................................................... 4  
2.2.2.2  Distribution ........................................................................................................................ 4  
2.2.2.3  Metabolism ........................................................................................................................ 4  
2.2.2.4  Elimination ........................................................................................................................ 4  
2.2.3  Clinical Experience with Dasatinib in CML and Ph+ ALL ..............................................................4  
2.2.4  Phase 1 Experience of Dasatinib in Solid Tumors other than Melanoma .........................................6  
2.2.5  Phase 2 Experience of Dasatinib in Melanoma Patients ...................................................................6  
2.3 Potential for Vaccine-Induced CD8+ T cell Targeting of Tumor Antigens versus Tumor Blood 
Vessel Antigens ......................................................................................................................... 7 
2.4 Immune Dysfunction in Patients with Advanced-Stage Solid Cancers .................................... 8 
2.5 Dendritic Cells ......................................................................................................................... 10 
2.6 Type-1 Polarized DC ............................................................................................................... 10 
2.7 Improved Anti-Tumor Efficacy for Combined Dasatinib + Vaccine Therapy........................ 11 
3.
 STUDY RATIONALE .................................................................................................................. 14 
3.1 I
mportance and Rationale for the Trial ................................................................................... 14 
3.2 Rationale for Vaccine Dose, Route of Administration and Schedule ..................................... 15 
4. STUDY DESIGN .......................................................................................................................... 16 
4.1 Leuk
apheresis .......................................................................................................................... 16 
4.2 Vaccine .................................................................................................................................... 17 
4.2.1  Formulation ..................................................................................................................................... 17 
4.2.2  Storage and preparation .................................................................................................................. 17 
4.2.3  Administration ................................................................................................................................  17 
4.2.4  Anticipated Adverse Events (Vaccine) ........................................................................................... 17 
4.3 Dasatinib .................................................................................................................................. 18 
4.3.1  Packaging and Labeling .................................................................................................................. 18 
4.3.2  Storage ............................................................................................................................................ 18 
4.3.3  Handling and Dispensing ................................................................................................................ 18 
4.3.4  Drug Ordering and Accountability .................................................................................................. 19 
4.3.5  Safety of Dasatinib in Clinical Studies in CML and Ph+ ALL ....................................................... 19 
4.3.6  Laboratory Abnormalities ............................................................................................................... 21 
4.3.7  Anticipated Adverse Events (Dasatinib) ......................................................................................... 21 
4.3.7.1  Myelosuppression ............................................................................................................ 21 
4.3.7.2  Bleeding Related Events .................................................................................................. 21 
4.3.7.3  Fluid Retention ................................................................................................................ 22 
4.3.7.4  QT Prolongation .............................................................................................................. 22 
5. STUDY TREATMENT PLAN ...................................................................................................... 22 
5.1
 Dasatinib Administration ........................................................................................................ 22 
5.2 Vaccine administration ............................................................................................................ 23 
5.3 Duration of Study Treatment ................................................................................................... 23 
5.4 Duration of Follow Up ............................................................................................................ 24 
6. STUDY CALENDAR ................................................................................................................... 24 
7. DOSE- LIMITING TOXICITIES ................................................................................................... 25 
7.1 Definition of Dose-Limiting Toxicity ..................................................................................... 25 
7.2 Dasatinib Dosing delays/modifications ................................................................................... 26 
7.2.1  Grades 1 or 2 hematologic or non-hematologic toxicities ...............................................................  26 
7.2.2  Grades 3 or 4 hematologic or non-hematologic toxicities ...............................................................  26 
7.3 Vaccine Dosing delays/modifications ..................................................................................... 26 
8. PATIENT SELECTION ................................................................................................................ 26 
8.1 Inclusion Criteria ..................................................................................................................... 26 
8.2 Exclusion Criteria ................................ .................................................................................... 27 
8.3
 Inclusion of Women and Minorities ........................................................................................ 28 
8.4 General Concomitant Medication and Supportive Care Guidelines........................................ 28 
8
.4.1 Bisphosphonates ............................................................................................................................. 29 
8.4.2  Antacids .......................................................................................................................................... 29 
8.4.3  Medications that prolong the QT interval ....................................................................................... 29 
8.4.4  Medications that affect CYP3A4 .................................................................................................... 29 
9. RESEARCH SAMPLES ................................................................................................................ 30 
9.1 B
iopsy tissue ........................................................................................................................... 30 
9.2 Blood samples ......................................................................................................................... 31 
10. CORRELATIVE STUDIES .......................................................................................................... 31 
10.1  Immune Monitoring Analysis of TBVA-specific CD8+ T cell responses (Primary Endpoint).
 
................................................................................................................................................. 31 
10.2  Quantitation of CD8+ T cells, Treg, MDSC and blood vessels in melanoma biopsy tissue .... 32 
10.3  Tr
eg analysis in PBMC ............................................................................................................. 32 
10.4  MDS
C Analysis in PBMC ...................................................................................................... 33 
10.5  EphA
2 Protein Levels in tumor biopsies ................................................................................. 33 
10.6  CXCL10 Levels in Patient Serum ........................................................................................... 33 
11. MEASUREMENT OF EFFECT .................................................................................................... 33 
11.1  Antitumor Effect...................................................................................................................... 34 
1
1.1.1  Definitions ....................................................................................................................................... 34 
11.1.2  Disease Parameters ......................................................................................................................... 34 
11.1.3  Methods for Evaluation of Measurable Disease .............................................................................. 35 
11.1.4  Response Criteria ............................................................................................................................ 38 
11.1.4.1  Evaluation of Target Lesions ......................................................................................... 38 
11.1.4.2 Evaluation of Non-Target Lesions ................................................................................. 38 
11.1.4.3 Evaluation of Best Overall Response ............................................................................ 38 
11.1.5  Duration of Response ...................................................................................................................... 39 
11.1.6  Progression-Free Survival ............................................................................................................... 40 
12. STATISTICAL CONSIDERATIONS ........................................................................................... 40 
12.1  Study Design ........................................................................................................................... 40 
12.2  Safety Monitoring.................................................................................................................... 40 
12.3  Sampl
e Size/Accrual Rate ....................................................................................................... 41 
12.4  Data Analysis .......................................................................................................................... 41 
12.4.1  Analysis Sets ................................................................................................................................... 41 
12.4.2  Baseline Characteristics .................................................................................................................. 41 
12.4.3  Safety Profile .................................................................................................................................. 41 
12.4.4  Efficacy Analysis ............................................................................................................................ 42 
12.5  Reporting and Exclusions ........................................................................................................ 42 
12.5.1  Evaluation of toxicity ...................................................................................................................... 42 
12.5.2  Evaluation of response .................................................................................................................... 42 
13. DATA SAFETY MONITORING PLAN ...................................................................................... 43 
14.
 ADVERSE EVENT REPORTING ................................................................................................ 44 
14.1  Adverse event definitions ........................................................................................................ 44 
14.2  Recording/Reporting requirements ......................................................................................... 45 
14.2.1  Eliciting AE Information ................................................................................................................ 45 
14.2.2  Recording Requirements ................................................................................................................. 45 
14.2.2.1 Abnormal Test Findings ................................................................................................  46 
14.2.2.2 Causality and severity assessment ................................................................................. 46 
14.3  Reporting of Suspected Adverse Reactions ............................................................................ 46 
14.4  Review of Safety Information: Sponsor Responsibilities[1] ................................................... 47 
14.5  Reporting of Adverse Reactions to the FDA ........................................................................... 47 
14.5.1  Written IND safety reports .............................................................................................................. 47 
14.5.2  Telephoned IND safety reports – fatal or life-threatening suspected adverse reactions .................. 48 
14.6  Reporting adverse events to the responsible IRB .................................................................... 48 
15. WITHDRAWAL OF SUBJECTS DUE TO ADVERSE EVENTS .............................................. 48 
16. QUALITY CONTROL AND QUALITY ASSURANCE ............................................................. 49 
17. D
ATA HANDLING AND RECORD-KEEPING ......................................................................... 49 
18. ETHICS ......................................................................................................................................... 49 
18.1  Institutional Review Board (IRB) Approval ........................................................................... 49 
18.2  Ethical and Scientific Conduct of the Clinical Study .............................................................. 50 
18.3  Subject Informed Consent ....................................................................................................... 50 
19. REFERENCES .............................................................................................................................. 51 
 
LIST OF ABBREVIATIONS 
AE Adverse event  
ANC  Absolute Neutrophil Count  
BID Twice a Day  
BMS  Bristol -Myers Squibb Company  
CBC Complete Blood Count  
CTCAE  Common Terminology Criteria for Adverse Events  
DLT Dose Limiting Toxicity  
DSMB  Data Safety Monitoring Board  
ECOG  Eastern Cooperative Oncology Group  
EKG  Electrocardiogram  
ESR Expedited Safety Report  
FDA Food and Drug Administration  
FSH Follicle -Stimulating Hormone  
GCP Good Clinical Practice  
HCG  Human Chorionic Gonadotropin  
HIPAA  Health Insurance Portability and Accountability Act  
HRT Hormone Replacement Therapy  
IB Investigators’ Brochure  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
IND Investigational New Drug (Application)  
IRB Institutional Review Board  
NCI National Cancer Institute  
NSAE  Non-Serious Adverse Event  
PFS Progression Free Survival  
PO By Mouth  
PR Partial Response  
QD Once Daily  
QoL Quality Of Life  
SAE Serious Adverse Event  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
ULN  Upper Limit of Normal  
WBC  White Blood Count  
WOCBP  Women of Child -Bearing Potential  
 
UPCI 12-048 1 02-15-2016 1. OB JECTIVES 
1.1 P rimary Objectives 
To determine the effect of the addition of dasatinib on the proportion of HLA- A2+ melanoma 
pa
tients that exhibit improved peripheral blood CD8+ T cell responses against 3 or more peptide 
e
pitopes after active vaccination with Type I-polarized autologous dendritic cell ( DC1) vaccine 
incorporating 6 tumor blood vessel-associated antigen (TBVA)-derived peptides.  
1.2 S econdary Objectives 
 To determine the safety and feasibility of a regimen consisting of the combination of 
dasatinib and vaccine. 
 To determine the objective response rate by RECIST 1.1 of melanoma patients treated 
with 
the combination of dasatinib and vaccine. 
 To de
termine the progression-free and overall survival of patients treated with the 
c
ombination of dasatinib and vaccine. 
 To determine the quantitative effect of treatment on the following immunological 
endpoints; a) number of CD8+ T cells infiltrating into melanoma lesions; b) number of 
suppre
ssor cell populations and blood vessels in melanoma tumor biopsies; c) number of 
suppressor cell populations in patients peripheral blood, d) level of EphA2 protein 
expression in tumor biopsies, and e) serum concentration of the T cell-recruiting 
chemokine CXCL10/IP-10. 
2. B ACKGROUND 
2.1 M elanoma 
The incidence of melanoma continues to rise at an alarming pace. The American Cancer Society 
e
stimates that over 70,000 patients will be diagnosed with melanoma in 2011 with an estimated 
death toll of over 8,700 deaths (1). Early stages of the disease are surgically curable and adjuvant 
ther
apy of high risk disease is modestly effective in preventing recurrent metastatic disease. 
Once metastatic, melanoma is incurable with very high disease-fatality rates (2). Few agents 
have shown clinical benefit in this setting and none has shown a survival advantage, until 
ipi
limumab, most recently with the first ever metastatic melanoma trial to show improvement of 
ove
rall survival leading to FDA approval in March 2011. Hydroxyurea was the first agent to get 
FDA approval in 1967 followed by dacarbazine in 1971 which quickly became the “standard of 
care” as no other agent, singly or in combination, achieved a survival advantage over 
dacarbazine (3 -5). Immunotherapy has achieved limited success with high-dose bolus IL-2 
leading to durable responses in a small subset of patients (5-15%; ref. 6). The approval of 
ipilimumab is likely to alter the therapeutic landscape of metastatic melanoma but it should be 
noted that only 10-15% of patients respond and not all achieve durable responses (7). Even more 
pr
omise is associated with the advent of highly selective BRAF-targeted agents that have led to 
 
UPCI 12-048 2 02-15-2016 the hig
hest response rates seen in melanoma in patients that harbor the BRAF mutation (8). 
W
hile this is clearly encouraging, to date no durable responses have been described with BRAF 
inhibitors and those are only available for the 40-50% of patients that have the mutation. 
Therefore there continues to be an urgent need to develop therapeutic strategies that offer long 
term control of the disease. 
Mutation-directed therapy has expanded the therapeutic opportunities for c-KIT-mutated 
melanomas. Unlike melanomas that occur in chronic sun-damaged areas, melanomas arising in 
non-sun exposed areas such as the mucosal surfaces, palms, soles, and nail beds are thought to 
re
sult from different risk factors and perhaps different oncogenes. Indeed, melanomas with 
oncogenic mutations in c-KIT have been reported in several studies. Recently, c-KIT -activating 
mutations were reported in 21% of mucosal melanomas, 11% of acral melanomas, and 16.7% of 
melanomas arising in chronically sun-damaged skin (9 - 13). 
2.2 Dasat inib  
Dasatinib (BMS-354825; NSC-732517) is a potent, broad spectrum ATP-competitive inhibitor 
of
 5 critical oncogenic tyrosine kinases/kinase families: BCR-ABL, SRC, c-KIT, PDGFR, and 
ephrin (Eph) receptor kinases. Overexpression or activation of these kinases plays a critical role 
in the etiology of various cancer types, as well as the malignant behavior associated with these 
diseases, such as unregulated proliferation and metastasis. The Philadelphia chromosome and 
resultant constitutively expressed BCR-ABL protein tyrosine kinase (PTK) is present in > 90-
95% of patients with CML and 20% to 30% of adult patients with ALL.  BCR-ABL activity is 
required for the cancer-causing ability of this protein. Dasatinib is ~500-fold more potent than 
ima
tinib in inhibiting BCR-ABL by binding to both active and inactive conformations of c-ABL, 
whereas imatinib only binds to the inactive state.  This difference in binding may be responsible 
for the increased potency of dasatinib over imatinib (14). 
Da
satinib is indicated for the treatment of newly diagnosed adults with CML in chronic phase, 
the treatment of adults with chronic, accelerated, myeloid or lymphoid blast phase CML with 
resistance or intolerance to prior therapy including imatinib, and the treatment of adults with Ph+ 
ALL with resistance or intolerance to prior therapy (14). 
2.2.1 P reclinical Anti-tumor Activity 
2.2.1.1 In Vitro Molecular Studies 
Dasatinib competes with ATP for the ATP-binding site in the kinase domain of selected protein 
tyrosine kinases (PTKs) and has been shown to inhibit at least five protein tyrosine 
kinases/kinase families: SRC family kinases, BCR-ABL, c-KIT, EphA2 and the PDGFR  
receptor. Dasatinib is much more potent than imatinib mesylate. Dasatinib was 260-, 8-, 60-, and 
>
1000-fold more potent than imatinib versus BCR-ABL, c-KIT, PDGFR , and SRC kinases, 
respectively (14). 
 
UPCI 12-048 3 02-15-2016 2.2.1.2
 Cellular Studies 
Dasatinib inhibits the BCR-ABL kinase with an in vitro  IC50 of 3 nM, a potency that was 
260-fold greater than that of imatinib mesylate (IC50 = 790 nM). In cellular assays, dasatinib 
kil
led or inhibited the proliferation of all BCR-ABL dependent leukemic cell lines tested to date. 
Dasatinib also demonstrated undiminished antitumor activity against several preclinically- and 
c
linically-derived models of imatinib mesylate resistance. These results demonstrate that 
dasatinib is effective in reducing the proliferation or survival of both imatinib mesylate-sensitive 
and resistant cells, and its inhibitory activity is not solely dependent on BCR-ABL. 
2.2.1.3 In Vivo Studies 
The
 activity of dasatinib against CML cells in vitro  was reproduced in vivo against several 
human CM
L xenograft models grown subcutaneously in SCID mice. Against the K562/imatinib 
mesylate/R CML model, dasatinib was curative in 100% of the treated animals. In contrast, at its 
optimal dose and schedule, imatinib mesylate was inactive. 
Dasatinib exhibited in vivo  antitumor activity in a broad spectrum of solid tumor types including 
the r
habdomyosarcoma line RD1 implanted in nude mice. The activity appeared to be from a 
cytostatic rather than cytotoxic effect. 
2.2.1.4 Preclinical Toxicology 
Single or repeated oral administration of dasatinib principally affected the gastrointestinal (GI) 
tract, including the liver, the hematopoietic and lymphoid systems in rats and monkeys. Other 
prominent effects after single oral administration of dasatinib included renal and cardiac toxicity 
in ra
ts at lethal doses, and cutaneous hemorrhage in monkeys. Dasatinib can also affect the 
immune system and bone turnover. 
Dasatinib in vitro  activity in the HERG/IKr and Purkinje-fiber assays indicated a moderate 
liabil
ity for prolongation of cardiac ventricular repolarization (QT interval) in the clinic. 
However, there were no dasatinib-related changes observed in electrocardiograms, nervous 
system function, respirations and heart rate, blood pressure, or arterial oxygen saturation in 
single-dose, 10-day, or 1-month oral toxicity studies in monkeys. 
Dasatinib was found to exhibit a profile of broad-spectrum platelet inhibition best typified by 
anti-platelet agents such as the GPIIb/IIIa antagonists, integrelin and abciximab. 
Finally, modulation of SRC kinase activity could also affect osteoclast morphology and function 
and bone remodeling. This effect could potentially result in an increase in bone mineral density 
and a phenotype analogous to osteopetrosis (14).  
2.2.2 C linic al Pharmacokinetics 
The pharmacokinetics of dasatinib has been evaluated in 229 healthy patients and in 137 patients 
with l
eukemia. 
 
UPCI 12-048 4 02-15-2016 2.2.2.1
 Absorption 
Maximum plasma concentrations (C max) of dasatinib are observed between 0.5 and 6 hours 
(Tmax) f
ollowing oral administration. Dasatinib exhibits dose proportional increases in AUC and 
linear elimination characteristics over the dose range of 15 mg to 240 mg/day. The overall mean 
terminal half-life of dasatinib is 3-5 hours (14).  
Da
ta from a study of 54 healthy patients administered a single, 100-mg dose of dasatinib 
30 minutes following consumption of a high-fat meal resulted in a 14% increase in the mean 
AU
C of dasatinib. The observed food effects were not clinically relevant.  
2.2.2.2 Distribution 
In patients, dasatinib has an apparent volume of distribution of 2505 L, suggesting that the drug 
is ex
tensively distributed in the extravascular space. Binding of dasatinib and its active 
metabolite to human plasma proteins in vitro  was approximately 96% and 93%, respectively, 
with no conc
entration dependence over the range of 100-500 ng/mL (14).  
2.2.2.3
 Metabolism 
Dasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4. 
CYP3A4 was the primary enzyme responsible for the formation of the active metabolite. Flavin-
containing monooxygenase 3 (FMO-3) and uridine diphosphate-glucuronosyl transferase (UGT) 
e
nzymes are also involved in the formation of dasatinib metabolites. In human liver microsomes, 
dasatinib was a weak time-dependent inhibitor of CYP3A4.  
The
 exposure of the active metabolite, which is equipotent to dasatinib, represents approximately 
5% of the dasatinib AUC. This indicates that the active metabolite of dasatinib is unlikely to play 
a major role in the observed pharmacology of the drug. Dasatinib also had several other inactive 
oxidative metabolites.  
2.2.2.4 Elimination 
Elimination is primarily via the feces. Following a single oral dose of [14C]-labeled dasatinib, 
approximately 4% and 85% of the administered radioactivity was recovered in the urine and 
feces, respectively, within 10 days. Unchanged dasatinib accounted for 0.1% and 19% of the 
administered dose in urine and feces, respectively, with the remainder of the dose being 
metabolites. 
2.2.3 C linical Experience with Dasatinib in CML and Ph+ ALL 
Four single-arm multicenter studies were conducted to determine the efficacy and safety of 
dasatinib in patients with CML or Philadelphia chromosome-positive acute lymphoblastic 
leukemia (Ph+ ALL) resistant to or intolerant of treatment with imatinib. Resistance to imatinib 
included failure to achieve a complete hematologic response (within 3–6 months) or major 
c
ytogenetic response (by month 12) or progression of disease after a previous cytogenetic or 
 
UPCI 12-048 5 02-15-2016 he
matologic response. Imatinib intolerance included inability to tolerate 400 mg or more of 
imatinib per day or discontinuation of imatinib because of toxicity. The studies are ongoing. The 
results are based on a minimum of 6 months follow-up after the start of dasatinib therapy. Most 
patients had long disease histories with extensive prior treatment, including imatinib, cytotoxic 
chemotherapy, interferon, and stem cell transplant. The maximum imatinib dose had been 400–
600 mg/day in about one-half of the patients and > 600 mg/day in the other half (14).  
All p
atients were treated with dasatinib 70 mg, twice a day, on a continuous basis. The median 
dura
tions of treatment were between 2.8 - 5.6 months (14).  
The
 primary efficacy endpoint in chronic phase CML was major cytogenetic response (MCyR), 
defined as elimination (complete cytogenetic response, CCyR) or substantial diminution (by at 
least 65%, partial cytogenetic response) of Ph+ hematopoietic cells. The primary endpoint in 
accelerated phase, myeloid blast phase, and lymphoid blast phase CML, and Ph+ ALL was major 
hematologic response (MaHR), defined as either a complete hematologic response or no 
evidence of leukemia as defined in Table 1. 
Most cytogenetic responses occurred after 12 weeks of treatment, when the first cytogenetic 
analyses were performed. Hematologic and cytogenetic responses were stable during the 6-
month follow-up of patients with chronic phase, accelerated phase, and myeloid blast phase 
CML. The median durations of major hematologic response were 3.7 months in lymphoid blast 
CML and 4.8 months in Ph+ ALL.  
There were no age- or gender-related response differences (14). 
T
able 1: Efficacy in Dasatinib Clinical Studies in CML and Ph+ ALL (All Treated Populations)a 
 Chronic 
(n=186)  Accelerated  
(n=107)  Myeloid 
Blast  
(n=74)  Lymphoid 
Blast  
(n=42)  Ph+ ALL  
(n=36)  
Hematologic  
Response Rateb (%) 
MaHR (95% CI)  n/a 59 (49 –68) 32 (22 –44) 31 (18 –47) 42 (26 –59) 
 CHR (95% CI)  90 (85 –94) 33 (24 –42) 24 (15 –36) 26 (14 -42) 31 (16 –48) 
 NEL (95% CI)  n/a 26 (18 –36) 8 (3–17) 5 (0.6 –16) 11 (3.1–26) 
Cytogenetic  
Responsec (%) 
MCyR (95% CI)  45 (37 –52) 31 (22 –41) 30 (20 –42) 50 (34 –66) 58 (41 –74) 
 CCyR  (95% CI)  33 (26 –40) 21 (14 –30) 27 (17 –39) 43 (28 –59) 58 (41 –74) 
a Numbers in bold font are the results of primary endpoint. 
b Hematologic response criteria (all responses confirmed after 4 weeks): 
Major hematologic response: (MaHR) = complete hematologic response (CHR) + no evidence of leukemia (NEL).  
CHR (chronic CML): WBC  institutional ULN, platelets <450,000/mm3, no blasts or promyelocytes in peripheral blood, <5% myelocytes 
plus metamyelocytes in peripheral blood, basophils in peripheral blood  institutional ULN, and no extramedullary involvement. 
 
UPCI 12-048 6 02-15-2016 C
HR (advanced CML/Ph+ ALL): WBC  institutional ULN, ANC 1000/mm3, platelets ≥100,000/mm3, no blasts or promyelocytes in 
peripheral blood, bone marrow blasts 5%, <5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood 
 institutional ULN, and no extramedullary involvement. 
NEL: same criteria as for CHR but ANC 500/mm3 and <1000/mm3, and/or platelets 20,000/mm3 and 100,000/mm3. 
c Cytogenetic response criteria: complete (0% Ph+ metaphases) or partial (>0%–35%). MCyR (0%–35%) combines both complete and partial 
responses. 
n/a = not applicable. 
 
2.2.4 P hase 1  Experience of Dasatinib in Solid Tumors other than Melanoma 
In a Phase 1 study (CA180003) conducted by Bristol-Myers Squibb (BMS), dasatinib was 
a
dministered on a twice a day schedule to 42 patients with refractory solid tumor. To date, doses 
up to 160 m
g, twice a day, on a 5-day on/2-day off schedule have been administered. A dose of 
120 mg
, twice a day, continuous daily schedule is currently under investigation.  
No se
vere clinical toxicity has been encountered. Gastrointestinal symptoms were reported in 
most patients, fatigue was reported in 17 patients (40%) and rash in 10 patients (24%). Edema, 
letha
rgy and headache were uncommon and appear to be dose-related. Grade 3 asymptomatic 
hypocalcemia was considered dose-limiting in one subject, Grade 2 rash was considered dose-
limiting in two other patients, and Grade 2 nausea and vomiting (with dysarthria, 
lightheadedness and lethargy in a 49 kg subject taking concurrent diazepam) was considered 
dose-limiting in one subject. 
In another Phase 1 study (CA180021), dasatinib was administered on a once daily schedule to 24 
pa
tients at doses up to 180 mg. Pleural effusions were observed in three patients at the 180 mg 
dose 
level (one with pneumonia and two with malignant effusion). A dose of 250 mg, once daily, 
is cur
rently under consideration. Hypocalcemia, GI symptoms, and skin rash have been mild and 
infr
equent. 
To date, the safety profile in solid tumor patients has been similar to that in chronic phase CML 
pa
tients with the exception of severe myelosuppression, which has not been observed in solid 
tum
or patients and is considered related to efficacy against the leukemia as noted above, and 
se
vere bleeding which is secondary to thrombocytopenia in most instances (14).  
2.2.5 P hase 2  Experience of Dasatinib in Melanoma Patients 
Kluger et al.  (15) have recently reported results of their Phase 2 study in which 39 patients with 
a
dvanced-stage, chemotherapy-naïve, unresectable melanoma received dasatinib twice daily in 
order to assess treatment impact on objective response rates and progression-free survival (PFS), 
a
s well as, any associated toxicities. The initial dosing of 100 mg, twice daily, was reduced to 70 
mg, twice daily, after treating 17 patients due to dose-limiting toxicities including fatigue, 
d
ypsea, and pleural effusion. Two patients exhibited partial response to therapy, while an 
a
dditional 3 patients displayed minor responses, with a median PFS of 8 weeks and 13% of 
pa
tients with a PFS of at least 6 months. Although the study failed to meet its clinical endpoints 
of a 30% response rate or 6-month PFS, and it displayed minimal efficacy as a single agent in 
unselected patients, the Kluger study suggested potential biased activity of dasatinib in patients 
 
UPCI 12-048 7 02-15-2016 without
 c-KIT mutations. This suggestion will be further inspected in an ongoing Eastern 
Cooperative Oncology Group (ECOG) Phase 2 study investigating the activity of dasatinib in 
patients with c-KIT mutated melanoma. Given the possibility of reduced clinical benefit for 
dasatinib in patients with c-KIT mutant melanomas, and in the absence of additional insights 
from the open ECOG trial, we have chosen to exclude such patients in this protocol. 
Regardless of the melanoma patient cohort selected for inclusion, however, Hersey et al.  (16) 
sugg
est that receptor tyrosine kinases like dasatinib will exert greatest clinical benefit when 
integrated in combination therapy designs, such as the current dasatinib + vaccination schema.  
2.3 P otential for Vaccine-Induced CD8+ T cell Targeting of Tumor Antigens versus 
Tumor Blood Vessel Antigens 
The finding of T lymphocyte infiltrates in melanomas and other solid tumor types (17-19) 
resulted in a series of studies to evaluate the adoptive transfer of patient-derived T cells in 
customized adoptive immunotherapy (AIT) approaches. Tumor-infiltrating lymphocytes (TIL) 
isolated from cancer patients were expanded to large numbers ex vivo  using either rIL-2 or rIL-
2/r
IL-4 culture supplementation (20). These lymphocytes were then administered intravenously 
(IV) in combination with systemic rIL-2 therapy. However, the adoptive transfer of TIL 
a
ppeared no more effective than rIL-2 alone in promoting clinical benefit (20, 21). 
Studi
es performed using such T lymphocytes provided one of the first demonstrations of a T cell 
response to human melanoma through the development of a series of T cell lines. CD8+ T cell 
li
nes showed specificity for autologous tumor cells in terms of mediating lytic activity and in 
producing IFN-  (22, 23). More recent studies have gone on to define a vast array of melanoma-
a
ssociated antigens and their corresponding MHC restricting elements that allow for tumor cell 
recognition by specific CD8+ (i.e. HLA- A2- restricted among others; ref. 2 4) Melanoma cells 
(ove
r)express a broad range of antigens that are capable of being recognized by T cells (25), each 
of which may be considered for integration into clinical vaccine formulations for the treatment of 
patients diagnosed with this disease.  
Cancer vaccines based on tumor-associated antigens (TAA) have been extensively evaluated in 
both translational models and in the clinic (26). Although by most accounts TAA-based vaccines 
ha
ve been found to be immunogenic i n promoting increased frequencies of Ag-specific T cell 
responses in a large proportion of treated patients, they have only rarely proven curative (27). 
This limitation in efficacy may relate, at least in part, to the heterogeneity of cancer cells found 
within a given tumor lesion, particularly with regard to sub-population immunophenotypes. 
Hence, tumor cells expressing lower levels of MHC molecules, molecules associated with the 
antigen-presentation machinery and/or therapeutically targeted tumor antigens have clear 
survival advantages in the face of specific vaccination (28-30). Indeed, many times patients that 
have exhibited objective clinical responses to immunomodulatory therapies ultimately progress 
 
UPCI 12-048 8 02-15-2016 with t
umors characterized by defects in their antigen-processing machinery and 
immunophenotype (31, 32). 
A the
oretical means by which to promote anti-tumor immunity, while coordinately 
circumventing the immunophenotypic “instability” of cancer cells themselves, involves the 
development of vaccines targeting tumor-associated stromal cells, such as (myo)fibroblasts, 
vascular pericytes, and VEC (33-35). Conditioned by the cancer microenvironment, tumor-
a
ssociated blood vessel cells are believed to express phenotypes that distinguish them from 
comparable cell populations found in normal tissues, hypothetically allowing for their biased 
immune targeting by specific T effector cell populations (36-38). Interestingly, the prior 
vaccination of mice with fibroblast or endothelial cell lines has been reported to provide some 
degree of protection against subsequent tumor growth (39, 40). Furthermore, prophylactic 
peptide- and/or recombinant vaccines based on tumor blood vessel-associated antigens (TBVA) 
such 
as endoglin (CD105), NG2, PDGFR , VEGFR1, or VEGFR2 have been reported to 
pr
ovide partial protection against challenge with tumor cell lines that fail to express these 
antigens, presumably based on T cell-mediated anti-neovascular activity in the TME (41-47). In 
a very limited number of studies employing therapeutic models, VEGFR1 and VEGFR2 peptide-
based vaccines were shown capable of modestly slowing the progressive growth of subcutaneous 
(SQ) tumors in mice (44, 47). 
W
e have recently reported that IL-12 cytokine gene-therapy of established tumors growing in 
H
LA-A2 transgenic mice (i.e. these mice exhibit a CD8+ T cell repertoire that mimics that of 
H
LA-A2+ humans) results in CD8+ T cell-mediated protective immunity directed at host blood 
vessel cells within the tumor microenvironment (48). CD8+ T cells isolated from effectively-
tre
ated animals recognized a range of HLA- A2-presented peptides derived from TBVA. We 
have more recently shown (49) that vaccination of HHD mice with TBVA-derived peptides 
re
sults in protective immunity against multiple types of solid cancers (including melanoma) 
unde
r conditions that are non-permissive for direct T cell recognition of tumor cells. Indeed, 
when applied in the therapeutic setting, such vaccines can be curative, based on Type-1 CD8+ T 
c
ell targeting of tumor- (but not normal tissue-) associated blood vessel cells (vascular pericytes 
and/or endothelial cells). Since the efficacious peptides derived from the TBVA DLK1 (delta-
like kinase 1), EphA2, HBB (hemoglobin- ), NRP1 (neuropilin 1), RGS5 (regulator of G-
signaling protein 5) and TEM-1 (tumor endothelial marker-1) that bear identical sequences in 
mouse and man, and can be recognized by CD8+ T cells isolated from cancer patients (48), these 
tra
nslational data support the use of these specific peptides in vaccine formulations for HLA- A2+ 
patients with solid cancers, including melanoma. 
2.4 Imm une Dysfunction in Patients with Advanced-Stage Solid Cancers 
Type-1 (i.e, Th1 CD4+ T cell and Tc1 CD8+ T cell) responses play critical roles in the rejection 
 
UPCI 12-048 9 02-15-2016 of
 tumors (50, 51). Th1 cells secrete IFN-  and IL-2, both of which promote cellular immunity, 
in part by providing helper signals for the development of Tc1 (cytotoxic T) lymphocytes (50). 
Th2-type cells produce IL-4 and IL-5, and typically promote a humoral (i.e. antibody-mediated) 
immune response, while Th3 and regulatory T (T reg) cells produce immunosuppressive cytokines 
(IL-10/TFGβ) that can dampen both Type-1 and Type-2 immune responses (51). The majority of 
studies have indicated that the most prevalent cytokine profile observed in patients with 
melanoma is consistent with a Type-2 functional bias in situ  (52, 53). I n prior studies we found 
little evidence for local Type-1 immune responses within the tumor; i.) there is a minimal 
expression of mRNA encoding for IL-2 and IFN-  associated with TIL, and less than 5% of 
tum
or infiltrating lymphocytes (TIL) expressed the activation marker, IL-2R  (54). TIL were 
de
fective in their proliferative and cytotoxic capacities (54, 55), and there was also an 
impairment in Type-1 T cell responses against tumor-associated antigens in peripheral blood T 
cells harvested from RCC patients with active disease (52). An analysis of MAGE-6- and 
EphA
2-specific CD4+ T cells revealed the predominance of Type-2 responses (i.e. characterized 
b
y IL-5 but not IFN-  production) after in vitro  stimulation with autologous dendritic cells (DC) 
pulsed w
ith MAGE-6 and EphA2 peptide epitopes (52).  
Apoptosis may contribute to the immune dysfunction observed for T cells in cancer patients. In 
many solid cancers, a sizeable proportion of tumor-infiltrating lymphocytes (mainly T cells) 
exist
 in a pro-apoptotic state, and an even greater number of T cells undergo apoptosis following 
in vitro  stimulation (56). Peripheral blood T cells isolated from cancer patients are more sensitive 
to activation induced cell death (AICD) versus comparable T cell populations harvested from 
healthy normal donors (57, 58). Most recently we observed that tumor antigen-specific T cells in 
the peripheral blood of melanoma patients with active disease are more sensitive to apoptosis 
when c
ompared to influenza-specific T cells recovered from these same individuals (58).  
I
n addition to these intrinsic defects associated with anti-tumor T cells in melanoma patients, 
ther
e are also “extrinsic” mechanisms linked to the functional suppression of otherwise 
protective anti-tumor T cells. These include the increased numbers and function of T reg and 
MDSC observed to be enriched in cancer patients (59-62).  
There is growing evidence that CD4+CD25hi+regulatory T cells (T reg) may play an important role 
in suppressing the development of anti-tumor immunity in cancer patients (63). The frequency of 
Treg is elevated in tumor sites and/or the pe ripheral blood of patients with advanced tumors (59-
62). T reg cells can impair induction of both antigen-specific and nonspecific T cells in cancer 
patients (63) and predict reduced survival in multiple cancer cell types (64, 65). Relevant to 
ther
apy, experimental models have shown that removal of T reg cells facilitates the therapeutic 
e
fficacy of protective immunity. Depletion of T reg cells in m ouse models using anti-CD25 
antibody enhances anti-tumor activity (66). Furthermore, reducing peripheral blood T reg cell 
 
UPCI 12-048 10 02-15-2016 number
s in melanoma patients enhances immunocompetence and responsiveness to active 
immuni
zation (67-69). 
MDSC act to suppress T cell effector function, and represent a heterogeneous population of cells 
de
rived from the myeloid lineage that accumulate in tumor bearing hosts as a result of tumor 
induced alterations in myelopoiesis (70). MDSC have mostly been studied in mice where they 
are identified by the co-expression of CD11b and Gr-1, accumulate in lymphoid organs and 
tumors of tumor bearing mice, and mediate T cell impairment that is reversed with tumor 
removal or with CD11b+ or Gr-1+ cell depletion (71). MDSC have been described in human 
pa
tients with many cancers including kidney cancer (72, 73), where they are defined as cells that 
express the common myeloid marker CD33, but lack markers of mature myeloid cells such as the 
MHC class II molecule HLA-DR. The accumulation of these cells in the peripheral blood of 
advanced-stage cancer patients has been associated with a decrease in the number and 
effectiveness of peripheral blood DC, as well as a decrease in T cell expression of TCR-  
(signaling) chain and IFN-  production (70-73). Studies performed in metastatic patients suggest 
these
 inhibitory effects are mediated via MDSC-derived reactive oxygen species (ROS) and 
MDSC-induced depletion of key biosynthetic amino acids (i.e. arginine, cystine, cysteine and 
tryptophan; refs. (70-74). 
2.5 De ndritic Cells 
Pre-clinical studies using Dendritic Cells ( DC) to stimulate specific anti-tumor T cell responses 
ha
ve been encouraging (75-79). DC are the most potent antigen presenting cells (APCs), capable 
of efficiently internalizing and presenting antigen in the context of co-stimulatory signals and 
cytokines that are essential to the induction of effective long-lasting T cell-mediated immunity. 
Animal models have demonstrated that DC, pulsed ex vivo  with defined tumor antigens (peptide 
e
pitopes) or material derived from tumor cells, are capable of eliciting protective, antigen-
specific immune responses (75, 80). Importantly, clinical trials have confirmed that DC pulsed 
with defined (tumor) peptide epitopes or tumor cell lysates induce anti-tumor T cell responses, 
and that occasionally, such immunity coincides with complete tumor regression in late stage 
patient s (81-83). 
2.6 T ype-1 Polarized DC 
Two functions of dendritic cells are believed to be important for the ability of DC to induce 
Type-1 Th1 cells and Tc1; i.e. high co-stimulatory activity and high secreted protein levels of 
anti-cancer cytokines, especially IL-12 (79-83). Many previous clinical trials have relied on the 
use of either fully-matured DC exhibiting high stimulatory function but low IL-12 secretion, or 
immature DC that display low stimulatory/high IL-12 secretion functions. Using a novel culture 
method, it is now possible to generate mature DC that exhibit high levels of co-stimulatory 
activity and IL-12 production (84). Such DC are referred to as Type-1 polarized DC or DC1. In 
 
UPCI 12-048 11 02-15-2016 v
itro observations show that DC1 i nduce up to 50-fold higher frequencies of tumor antigen-
specific CD8+ T cells after in vitr o sensitization (the equivalent of vaccination) when compared 
to conventionally matured DCs that have been previously employed in clinical trials (84).  
In addition to their potent immunostimulatory function and high-level production capacity for 
Type-1 polarizing cytokines, DC1 exhibit a stable phenotype that is resistant to tumor-
associated immunosuppressive factors, including IL-10 and PGE 2 (84-87). This suggests the 
possibility of using DC1 as a biologic adjuvant to enhance the clinical efficacy of cancer 
vaccines, despite the immune suppressive environment known to exist in many patients with 
melanoma. 
Recently the original DC1 protocol based on fetal bovine serum-supplemented cultures has 
been modified to allow DC1 generation in serum-free media (84). This has facilitated the 
translati
on of DC1 into ongoing Phase 1/2 clinical trials being performed at the University of 
P
ittsburgh Medical Center (UPMC)/University of Pittsburgh Cancer Institute (UPCI) in the 
setting of melanoma (UPCI 03-118, BB-IND 11,754), colorectal cancer (UPCI 05-063; BB-IND 
13,234)
, and glioma (UPCI 05-115 ; BB-IND 12,415). Thus far clinical activity for vaccination 
has been observed in 2 of the initial 4 melanoma patients who completed treatment (1PR 12M+ 
in a pa
tient with Stage IIIb disease; 1 SD 11M+ in a patient with stage IV lung disease). The two 
first patients with resected metastatic CRC are undergoing follow-up for time to recurrence and 
immunologic evaluations. We also recently completed a Phase 1/2 DC1 ( 1-3 x 107 cells) + 
g
lioma peptide (derived from the EphA2 [specifically EphA2 883 -891 to be used in the current 
vaccine formulation], IL-13R 2, TKL-40 and gp100 antigens) vaccine trial of 22 HLA- A2+ 
pa
tients with malignant glioma (88). More than half of the patients exhibited vaccine-associated 
incr
eases against at least one of the 4 treatment peptides, with increased levels of serum IFN-  
and CXCL10/IP-10 post-vaccination. Nine patients achieved a PFS exceeding 12 months, with 
one
 patient developing a complete response to treatment. To date, these regimen have proven to 
be well-tolerated, with no untoward side effects observed in any of these settings.  
2.7 Im proved Anti-Tumor Efficacy for Combined Dasatinib + Vaccine Therapy 
Given our own and others’ recent reports supporting the ability of tyrosine kinase inhibitors 
(such as sunitinib and dasatinib) to mitigate at least a portion of the immunosuppressive circuits 
(i.e. regulatory T cells and myeloid-derived suppressor cells) present in cancer patients, we 
hypothesize that the co-application of dasatinib will increase the immunogenicity of specific 
vaccination protocols. 
We recently performed and published proof-of-concept, pre-clinical studies in which w e 
obser
ved superior anti-tumor efficacy for therapies combining TKI (sunitinib) + vaccination 
(D
C1/peptide) approaches (89). This was particularly evident when sunitinib was applied at the 
ti
me of the initial vaccination or the vaccine booster. Treatment effectiveness was associated 
 
UPCI 12-048 12 02-15-2016 with t
he acute loss of (and/or failure to recruit) cells bearing MDSC or T reg phenotypes within 
the melanoma microenvironment and the corollary, prolonged enhancement of specific Type-1 
CD8+ T cell responses in the melanoma-draining lymph node (TDLN) and the melanoma lesion 
itself. Enhanced Type-1 T cell infiltration of tumors was associated with treatment-induced 
expression of VCAM-1 and CXCR3 ligand chemokines (CXCL9/Mig, CXCL10/IP-10 and 
CXCL11/ITAC) in vascular/peri-vascular cells within the tumor microenvironment (TME), with 
the combined therapy benefits negated by administration of blocking antibodies against CXCR3 
or vascular cell adhesion molecule (VCAM)-1. These data support the ability of sunitinib to 
enhance the capacity of vaccines to elicit Type-1 CD8+ T cell responses in tumor-bearing hosts 
a
nd to concomitantly (re)condition the TME to become more receptive to the recruitment and 
prolonged therapeutic action of such vaccine-induced CD8+ T effector cells. More recently we 
ha
ve observed similar tendencies when combining dasatinib and DC1/peptide vaccines in murine 
melanoma models ( Fig. 1 ). 
Fig. 1. Combination dasatinib + DC1/peptide-based vaccination results in superior activation of specific CD8+ T 
cells and anti-tumor efficacy in a murine melanoma model. (A)  M05 (B16.OVA) melanoma cells were injected 
s.c. into syngenic C57BL/6 mice and allowed to establish for 10 days, at which time animals were randomized for 
tumor size and cohorts of 7 mice/group were left untreated, or they were treated with orally administered dasatinib 
(DAS; 0.1 mg/day for 7 consecutive days), a contralateral s.c. vaccine (VAC) consisting of 106 OVA peptide-pulsed 
dendritic cells (DC)  or a combination of DAS + VAC. Animals were then monitored for tumor growth ( B) and at 
day 34, 2 mice/group were sacrificed for analysis of specific T cell (isolated from the tumor-draining lymph node 
(TDLN) of tumor (TIL)) recognition of the OVA peptide based on IFN-  secretion as monitored by ELISA ( C). Day 
34 tumors were also isolated and analyzed for their content of myeloid-derived suppressor cells (MDSC; bearing a 
CD11b+Gr1+ phenotype) and regulatory T cells (Treg; bearing a CD4+Foxp3+ phenotype) by flow cytometry ( D); 
MO5 (B16.OVA) 
injected s.c .  
(2 x 105)
+/- oral Dasatinib (0.1 mg/day) 
on d10-16
+/- s.c. DC/OVA257-262
vaccines d10, d17
Monitor tumor size
TME marker analysis (d34)
Immune monitoring (d34)A B
10 20 30 40 500100200300400500Untreated
Dasatinib
Vaccine
DAS + VAC
M05 Tumor Size (mm2)
Days Post Tumor 
Inoculation D
7.3%
CD11b
Gr122.6% 2.5% 2.3%
4.3%
 8.3% 2.8% 2.1%
CD4Foxp3Untreated Dasatinib Vaccine DAS + VACC
01000200030004000
IFN-(pg/ml)
Untreated
Dasatinib
Vaccine
DAS + VAC
Untreated
Dasatinib
Vaccine
DAS + VACTDLN TIL
E
CD31 x
VCAM-1
xDAPICD31 x
CXCL10
xDAPIUntreated Dasatinib Vaccine DAS + VAC
0.3 +0.2 25.1 +6.3* 21.8 +7.9* 81.8 +6.0**
1.8 +1.5 17.8 +8.4* 26.8 +5.5* 162 +18******
**
**
**
MO5 (B16.OVA) 
injected s.c .  
(2 x 105)
+/- oral Dasatinib (0.1 mg/day) 
on d10-16
+/- s.c. DC/OVA257-262
vaccines d10, d17
Monitor tumor size
TME marker analysis (d34)
Immune monitoring (d34)A B
10 20 30 40 500100200300400500Untreated
Dasatinib
Vaccine
DAS + VAC
M05 Tumor Size (mm2)
Days Post Tumor 
InoculationB
10 20 30 40 500100200300400500Untreated
Dasatinib
Vaccine
DAS + VAC
M05 Tumor Size (mm2)
Days Post Tumor 
Inoculation D
7.3%
CD11b
Gr122.6% 2.5% 2.3%
4.3%
 8.3% 2.8% 2.1%
CD4Foxp3
7.3%
CD11b
Gr122.6% 2.5% 2.3%
 7.3%
CD11b
Gr122.6% 2.5%
 7.3%
CD11b
Gr122.6% 2.5% 2.3%
4.3%
 8.3% 2.8% 2.1%
 4.3%
 8.3% 2.8%
 4.3%
 8.3% 2.8% 2.1%
CD4Foxp3Untreated Dasatinib Vaccine DAS + VACC
01000200030004000
IFN-(pg/ml)
Untreated
Dasatinib
Vaccine
DAS + VAC
Untreated
Dasatinib
Vaccine
DAS + VACTDLN TIL
E
CD31 x
VCAM-1
xDAPICD31 x
CXCL10
xDAPIUntreated Dasatinib Vaccine DAS + VAC
0.3 +0.2 25.1 +6.3* 21.8 +7.9* 81.8 +6.0**
1.8 +1.5 17.8 +8.4* 26.8 +5.5* 162 +18******
**
**
**
 
UPCI 12-048 13 02-15-2016 p
ercentage of cells bearing the specified phenotype is reported in panel insets) and for expression of VCAM-1 and 
CXCL10 proximal to CD31+ vascular endothelial cells using immunofluorescence microscopy ( E); mean +/- SD 
number of cells over 10 high-power fields are reported in panel insets). Three experiments were performed 
independently, each yielding similar data, *p < 0.05 versus untreated; **p < 0.05 versus all other groups .  
F
ig. 2. Dasatinib (but not imatinib) pre-treatment of HLA- A2+ human melanoma cell-line Mel526 increases 
degradation of EphA2 and improves tumor cell recognition by EphA2-specific CD8+ T cells . In addition to its 
inhibitory action on src kinases, dasatinib has been reported to inhibit signaling through the receptor tyrosine kinase 
EphA2 (90) which is commonly over-expressed by human melanomas in situ (91) and shown to represent a critical 
oncogene in melanoma tumorigenic potential (92). We treated the human HLA- A2+, EphA2+ with various doses of 
dasatinib or imatinib for 24h and analyzed EphA2 protein by western blotting. Panel A reports the percentage of 
control EphA2 expression in the TKI-treated melanoma cells. This loss of EphA2 protein is due to the proteasome-
dependent degradation of the protein based on the ability of MG-132 and lactacystin to block protein loss (data not 
shown). Using flow cytometry ( B), we also showed that cell surface expression of EphA2, but not HLA-A2 class I 
molecules was reduced selectively after treatment with dasatinib. Finally, since proteasomal processing is required 
for the generation of many MHC class I-presented peptides to CD8+ T cells, we next analyzed whether TKI (0.5 
mg/ml) pre-treatment enhanced tumor cell recognition by anti-EphA2 CD8+ T cells based on their secretion of IFN-
after stimulation with these melanoma cells ( C). To validate the HLA- A2-restricted nature of T cell recognition, 
we showed that addition of the anti-HLA-A2 blocking antibody BB7.2 to T cell/melanoma cultures ablated specific 
IFN- production by the CD8+ T cells. *p < 0.05 versus control untreated tumor cells (Control) and dasatinib-treated 
tumor cells + BB7.2 antibody (DAS/BB7.2) .  
050100150200250300350
T Cells Only
Control
Control/BB7.2
DAS
DAS/BB7.2
SUT
SUT/BB7,2
IMAT
IMAT/BB7.2IFN-(pg/ml)
+ Mel526 
pre-treated with:*A
B
020406080100120 DAS
IMAT
% Control EphA2 Protein
0
0.1
0.5
1.0
[TKI] (g/ml)*
*
Control Ab
EphA2 Ab
EphA2 Ab+ IMAT 0.5 M
EphA2 Ab+ DAS 0.5 M
EphA2 HLA- A2EventsC
050100150200250300350
T Cells Only
Control
Control/BB7.2
DAS
DAS/BB7.2
SUT
SUT/BB7,2
IMAT
IMAT/BB7.2IFN-(pg/ml)
+ Mel526 
pre-treated with:*A
B
020406080100120 DAS
IMAT
% Control EphA2 Protein
0
0.1
0.5
1.0
[TKI] (g/ml)*
*
020406080100120 DAS
IMAT% Control EphA2 Protein
0
0.1
0.5
1.0
[TKI] (g/ml)*
*
Control Ab
EphA2 Ab
EphA2 Ab+ IMAT 0.5 M
EphA2 Ab+ DAS 0.5 M
EphA2 HLA- A2Events
Control Ab
EphA2 Ab
EphA2 Ab+ IMAT 0.5 M
EphA2 Ab+ DAS 0.5 MControl Ab
EphA2 Ab
EphA2 Ab+ IMAT 0.5 M
EphA2 Ab+ DAS 0.5 M
EphA2 HLA- A2EventsC
 
UPCI 12-048 14 02-15-2016 F
ig. 3. Proposed mechanism of action for dastinib + vaccine co-therapy. Dasatinib is proposed to mediate 
beneficial anti-tumor impact based on a series of effects including its acute inhibition of immunoregulatory cells 
(MDSC and Treg) and normalization of blood vasculature within the tumor microenvironment (TME), leading to 
reduced hypoxia and interstitial fluid pressure ( A). Stromal cells within the TME alter their expression of 
chemokines and adhesion molecules, such as CXCL10 and VCAM-1 that are required for recruitment and 
infiltration of protective CXCR3+VLA4+ Type-1 CD8+ T cells ( B). Dasatinib also mediates direct effects on EphA2+ 
melanoma cells, by increasing the proteolytic processing of this protein into T cell recognized peptide epitopes, 
leading to enhanced anti-tumor activity mediated by anti-EphA2 TIL in vivo  (C).  
 
3. S TUDY RATIONALE 
3.1 Im portance and Rationale for the Trial 
Current therapeutic approaches available for patients with advanced-stage melanoma remain 
inadequate, and existing approaches including those involving immunotherapy with cytokines 
and/or ta
rgeted strategies have resulted in disappointingly low rates of durable and complete 
responses. Correcting immune dysfunction in advanced-stage melanoma patients using TKI such 
as dasatinib is proposed to relicense the patient’s immune system to respond optimally to specific 
immunization.  The integration of antigens expressed by tumor-associated blood vessel cells 
provides a means to selective ly target the genetica lly- /antigenically-heterogeneous population of 
tumor cells in the advanced-stage melanoma patient. 
The current trial represents a pilot,  randomized,  Phase 2 study to determine the activity and 
safety of intradermal administration of αDC1s loaded with a mixture of six TBVA-derived 
VCAM-1
CXCL10  Pericyte
VECVaccine-Induced 
Tc1 (CD8+T cell)
EphA2
Peptide
MHC I
EphA2
ProteinMEL
DegradeRegulatory Cells
Vascular Norm.
Hypoxia, HIF1/2Kill
Cytokines
Tumor
Blood 
Vessels
Tc1 infiltrateA
BC
VCAM-1
CXCL10  Pericyte
VECVaccine-Induced 
Tc1 (CD8+T cell)
EphA2
Peptide
MHC I
EphA2
ProteinMEL
DegradeRegulatory Cells
Vascular Norm.
Hypoxia, HIF1/2Kill
Cytokines
Tumor
Blood 
Vessels
Tc1 infiltrateA
BC
 
UPCI 12-048 15 02-15-2016 pe
ptides at the time of, or a cycle prior to, starting study treatment with the TKI dasatinib. 
3.2 Rat ionale for Vaccine Dose, Route of Administration and Schedule 
We propose to analyze CD8+ T cell responses against the TBVA DLK1, EphA2, HBB, NRP1, 
R
GS5, and TEM1 in peripheral blood of HLA- A2+ melanoma patients prior to, during the course 
of
, and one month after the last dose of dasatinib. Based on the strong Type-1 polarizing 
potential of
 DC1 in vitro , we hypothesize that these vaccines will enhance Type-1 CD8+ T cell 
re
sponses against at least 3 of the 6 peptides included in the vaccine (particularly when patients 
re
ceive concurrent dasatinib administration, as this removes the regulatory action of MDSC/T reg 
suppressor cells). 
We chose to evaluate a mixture of six TBVA-derived epitopes to be applied to DC1s as an 
intradermal vaccine injection into 28 HLA- A2+ patients with advanced-stage melanoma. This 
c
hoice is based on the finding of superior anti-tumor efficacy in HLA-A2 transgenic tumor 
models for the pooled peptide vaccine approach and the relevance of the previously identified 
TBVA-derived peptides (which share sequence identity in both human and mouse TBVA) in the 
HLA- A2+ human patient setting (48, 49). Our combinational vaccine + dasatinib modeling 
sugg
est that optimal therapeutic benefit against established M05 melanoma occurred when 
sunitinib administration was initiated at the time of initial vaccination or at the time of boosting. 
Systemic review and meta-analysis of previous DC-based vaccine trials in cancer patients 
sugg
ests that: i.) vaccine-induced T cell responses are associated with beneficial clinical 
outcome; ii.) mature DC (such as DC1) were superior activators of specific immunity and a 
better clinical prognosis when compared to immature DC; iii.) while a threshold dose of DC is 
required in the vaccine in order to promote specific immunity, a vast increase in DC number over 
that threshold did not generally yield superior efficacy (93-98). A recent study by Verdijk et al.  
suggests that intradermal delivery of DC-based vaccines in patients with advanced stage 
melanoma was clinically equitable to the delivery of these cells directly into lymph nodes (95), 
while a report from Lesterhuis and colleagues argues that intradermal delivered DC-based 
va
ccines were superior to intranodal delivered vaccines in promoting melanoma-specific T cell 
activation in vivo (96). In  vivo  tracking of intradermal injected DC in melanoma patients 
sugg
ests that approximately 4% of the administered DC actually migrate to tissue-draining 
lymph nodes and that the delivery of approximately 5 x 105 (vaccine) DC are needed to promote 
c
linically-meaningful levels of antigen-specific T cells (95). By extrapolation, these figures 
indi
cate that intradermal injection of a vaccine containing approximately 107 mature antigen-
loade
d DC1 would be anticipated to provide a quasi-optimal degree of immune stimulation that 
may be associated with clinical benefit. Pre-clinical, clinical, and mathematical modeling all 
sugg
est that optimal vaccine-induced immunity and benefit to the tumor-bearing host can be best 
achieved through repeated immunization (3-5 vaccines) provided over a regular-interval 
 
UPCI 12-048 16 02-15-2016 sc
hedule (93-98). Since there is no consensus in the literature for an optimal time interval 
between the individual vaccinations, we have adopted a protocol involving 4 intradermal 
vaccines every 2 weeks, which is a commonly employed schedule for DC - based vaccines (96). 
4. S TUDY DESIGN 
This is a single-center, prospective randomized, pilot, Phase 2 trial evaluating the activity, safety 
a
nd immune effects of dasatinib given in combination with an autologous type-1 polarized DC 
vaccine. Dasatinib will be administered at the standard dose and schedule recommended by the 
F
DA (70 mg BID). The autologous type-I DC vaccine will be administered either prior to, or 
c
oncomitant with, the inititation of dasatinib administration. Patients will be vaccinated 
intradermally with the αDC1/peptide mixture on days 1 and  15 of every cycle on an outpatient 
ba
sis in the University of Pittsburgh Clinical and Translational Research Center (UPCI-CTRC). 
F
or those patients starting therapy with vaccine alone, dasatinib will be initiated on day 29 after 
receiving the first immunization. Unless patients are removed from study, they will be treated for 
a
t least 6 cycles or disease progression. In cases where there is continued clinical benefit and no 
additional vaccine product is available, patients can continue to be treated on single agent 
da
satinib. Additional leukapheresis procedures may be performed at the discretion of the 
I
nvestigator/sub-investigator for patients that derive benefit but require the production of 
additional vaccine. 
4.1 L eukapheresis 
Leukapheresis (3 hours, 180 minutes) is a minimal risk procedure. Prior to the procedure each 
subje
ct’s venous access will be evaluated. If a subject does not have acceptable venous access a 
phe
resis catheter will need to be put in place. All selected patients will undergo a single limited 
leuka
pheresis once they have been deemed eligible and prior to the first course of vaccination. If 
the pa
tients receive benefit from the vaccine, but require additional cells for vaccine production, 
the leukapheresis may be repeated at the discretion of the investigator. The additional 
leukapheresis will take about two hours (120 minutes) to complete. One time of the subject's 
blood volume will be processed per procedure. The product is delivered immediately to the 
UPCI Immunologic Monitoring and Cellular Products Laboratory (IMCPL) from the UPCI-
C
TRC. Additional leukapheresis procedures may be performed at the discretion of the 
I
nvestigator/sub-investigator for patients that derive benefit but require production of additional 
vaccine. 
Leukapheresed product will be immediately processed as described in the Chemistry, 
Manufacturing, and Control section of BB-IND 11754, and a part of it will be used for the first 
vaccination course (Week 1). The remainder of the product will be cryopreserved as described. If 
c
ytopenia (WBC < 2000/mm3 or platelets < 40,000/mm3) develops during, or as a result of, 
leukapheresis, the procedure will be postponed until recovery. This will not be considered an 
adverse event. Samples from each cell product will be obtained for hemoglobin, hematocrit, total 
 
UPCI 12-048 17 02-15-2016 W
BC, and differential and platelet count. 
4.2 Vac cine 
4.2.1 F ormulation 
Dendritic cells (DC) are derived from autologous (the subject’s own) adherent mononuclear cells 
(monocytes) in the peripheral blood obtained from leukapheresis. In this case, “biologic product” 
and “biologic substance” are the same. We prefer the term “biologic product.” 
The vaccine will be manufactured in the UPCI-IMPCL, under cGMP conditions. 
4.2.2 S torage and preparation 
The final product is placed in vials with labels identifying each unique vaccine lot and 
c
ryopreserved. DCs used in the vaccine will be suspended in 5% human serum albumin (HSA) 
and delivered to the clinic for administration. For preparation of the vaccines, the labeled vials of 
cryopreserved αDC1 are removed from storage in liquid nitrogen and quickly thawed in a 37C 
water bath. After 3 washes in sterile medium, thawed αDC1 will be suspended in saline with 5% 
human serum albumin (HSA), placed in sterile syringe for administration to the subject and 
de
livered to the clinic for administration, depending on time of notification, it can be as early as 
10 am. Each syringe will be labeled with a custom-designed label, identifying the subject and the 
vaccine. Both saline and HSA are clinical grade (NDC 0944-0490-01 and NDC 0338-0049 -31) 
and available from UPMC hospital pharmacy as injection products for humans.  
4.2.3 Admini stration 
The autologous type-I DC vaccine will be administered intradermally either prior to, or 
conc
omitant with, the initiation of dasatinib administration. The injections will be performed on 
an outpatient basis in the UPCI-CTRC. 
4.2.4 Anticipa ted Adverse Events (Vaccine) 
Dendritic cell-based vaccines have been extensively evaluated in thousands of cancer patients 
over the past 15 years (25, 27, 79, 81, 82, 95, 96) and found to be safe and extremely well-
tolerated. The experience of the UPMC/UPCI in trials involving vaccination with DC1 has 
similarly shown that this cellular therapy is safe (88). Since the toxicities observed for the TKI 
are not of an immunologic nature, we do not anticipate any increase in adverse event frequency 
or severity for the dasatinib + vaccine cohort (Arm B) to exceed the level previously observed 
for dasatinib alone. 
Dendritic cell vaccines carry a potential risk of development of autoimmune disease (such as 
lupus or vitiligo). Whereas development of vitiligo has been reported with similar vaccines 
a
dministered to melanoma subjects, and correlated with positive response to vaccination, other 
side-effects have not been reported. Based on the previous trials with DC-based vaccines, the 
chances of developing an allergic reaction to DC-based vaccines are rare. There is a chance that 
 
UPCI 12-048 18 02-15-2016 subj
ects could have an allergic reaction to the vaccine. 
4.3 Dasat inib 
Dasatinib is provided by BMS in 3 different strengths: 
Strength  Description  
5 mg white, round, film coated tablet  
20 mg white to off -white, biconvex, round, film coated tablet with either “20” or 
“BMS” debossed on one side and “527” on the other side  
50 mg white to off -white, biconvex, oval, film coated tablet with either “50” or 
“BMS” debossed on one side and “528” on the other side  
 
4.3.1 P ackaging and Labeling 
Dasatinib is supplied as 5 mg, 20  mg, and 50 mg film-coated tablets containing dasatinib with 
lac
tose monohydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl 
cellulose, and magnesium stearate. The tablet coating contains hydroxypropyl methylcellulose, 
titanium dioxide, and polyethylene glycol (triacetin in the 5 mg film-coated tablet). Tablets for 
c
linical studies are supplied in high-density polyethylene bottles containing a desiccant and 
cotton. The bottles are heat-induction sealed with child resistant caps.  
Each bottle is labeled in an open label manner. Labels contain, at a minimum, the following 
information: product name, tablet strength, batch number, directions for use, storage conditions, 
and appropriate caution statements. 
4.3.2 S torage 
Bottles containing dasatinib tablets should be stored at 15° - 25°C. 
The
 investigational product should be stored in a secure area according to local regulations. The 
investigator is responsible for ensuring that it is dispensed only to study patients and only from 
of
ficial study sites by authorized personnel, as dictated by local regulations. 
The investigator is responsible for ensuring that the investigational product is stored under the 
appropriate environmental conditions (temperature, light, and humidity). 
If concerns regarding the quality or appearance of the investigational product arise, do not 
dispense the investigational product, and contact BMS immediately. 
4.3.3 Ha ndling and Dispensing 
Procedures for proper handling and disposal of anticancer drugs should be considered. 
Dasatinib tablets consist of a core tablet (containing the active drug substance), surrounded by a 
film coating to prevent exposure of pharmacy and clinical personnel to the active drug substance. 
 
UPCI 12-048 19 02-15-2016 I
f tablets are crushed or broken, pharmacy and clinical personnel should wear disposable 
chemotherapy gloves. Personnel who are pregnant should avoid exposure to crushed and/or 
broken tablets. 
The Investigator (or assigned designee, i.e., study pharmacist) will dispense the proper number 
of each strength tablet to the subject to satisfy dosing requirements for the study. The containers 
provided to the subject should be labeled with proper instructions for use. The lot numbers, 
dosing start dates and the number of tablets for each dosage strength must be recorded on the 
drug accountability pages of record for the site. The subject must be instructed to return all 
unused dasatinib in the provided packaging at each subsequent visit. 
4.3.4 Dr ug Ordering and Accountability 
Initial Orders of dasatinib should be requested by completing the Dasatinib (Sprycel®) Drug 
Supply Form for Investigator Sponsored Studies and submitting the request form electronically 
via e-mail at least 5-7 business days before the expected delivery date. Deliveries will be made 
Tue
sday through Friday. 
Initial drug supply will be provided for a 12-week treatment period per subject. 
Please send drug supply form to: srcsupply@bms.com. 
Re-supply requests should be sent to the appropriate email address (see Section 4.3.4 ). Please 
check “Re-supply” on the drug supply form. Re-supply requests should be submitted at least 5-7 
business days before the expected delivery date. Deliveries will be made Tuesday through 
Friday. 
4.3.5 S afety of Dasatinib in Clinical Studies in CML and Ph+ ALL 
The data described below reflect exposure to dasatinib in 911 patients with leukemia from 1 
Phase 1 and 5 Phase 2  clinical studies. The median duration of therapy was 6 months (range 0–
19 mont
hs).  
The majority of dasatinib-treated patients experienced adverse drug reactions at some time. Drug 
was discontinued for adverse drug reactions in 6% of patients in chronic phase CML, 5% in 
a
ccelerated phase CML, 11% in myeloid blast phase CML, and 6% in lymphoid blast phase 
C
ML or Ph+ ALL.   
The
 most frequently reported serious adverse events (SAEs) included pyrexia (9%), pleural 
effusion (8%), febrile neutropenia (7%), gastrointestinal bleeding (6%), pneumonia (6%), 
thrombocytopenia (5%), dyspnea (4%), anemia (3%), cardiac failure (3%), and diarrhea (2%).  
All treatment-emergent adverse events (excluding laboratory abnormalities), regardless of 
relationship to study drug, that were reported in at least 20% of the patients in dasatinib clinical 
studies are shown in Table 2 . 
 
UPCI 12-048 20 02-15-2016  
T
able 2. Adverse Events Reported ≥20% in Clinical Studies in CML and Ph+ ALL 
 
Table 3. CTC Grades 3/4 Laboratory Abnormalities in Clinical Studies in CML and Ph+ ALL 
 
Chronic Phase  
(n=488)  Accelerated Phase  
(n=186)  Myeloid 
Blast Phase  
(n=132)  Lymphoid Blast 
Phase and  
Ph+ ALL  
(n=105)  
 Percent (%) of Patients  
Hematology Parameters      
 Neutropenia  49 74 83 81 
 Thrombocytopenia  48 83 82 83 
 Anemia  18 70 70 51 
Biochemistry Parameters      
 Hypophosphatemia  11 13 23 21 
 Hypocalcemia  2 9 20 15 Preferred Term  All Patients  
(n=911)  Chronic 
Phase  
(n=488)  Accelerated 
Phase  
(n=186) Myeloid 
Blast 
Phase  
(n=132)  Lymphoid 
Blast Phase 
and 
Ph+ ALL  
(n=105)  
All 
Grades  Grades 3/4  Grades 3/4  
Percent (%) of Patients  
Fluid Retention  50 9 6 6 23 9 
 Superficial Edema  36 1 0 2 3 2 
 Pleural Effusion  22 5 3 3 14 8 
Diarrhea  49 5 3 10 8 6 
Headache  40 2 2 2 4 6 
Hemorrhage  40 10 3 18 23 17 
Musculoskeletal Pain  39 4 2 3 6 13 
Pyrexia  39 5 1 5 13 9 
Fatigue  39 3 2 4 4 8 
Skin Rash  35 1 1 1 1 4 
Nausea  34 1 <1 0 5 2 
Dyspnea  32 6 5 7 11 9 
Cough  28 <1 <1 1 1 0 
Infection  
(including bacterial,  
viral, fungal, non -
specified)  34 7 4 8 15 13 
Infection/Inflammation  26 1 1 1 5 1 
Abdominal Pain  25 2 1 2 4 6 
Pain  26 2 <1 1 5 4 
Vomiting  22 1 1 2 2 2 
Febrile Neutropenia  9 8 2 11 17 20 
 
UPCI 12-048 21 02-15-2016  
Chronic Phase  
(n=488)  Accelerated Phase  
(n=186)  Myeloid 
Blast Phase  
(n=132)  Lymphoid Blast 
Phase and  
Ph+ ALL  
(n=105)  
 Elevated SGPT (ALT)  1 4 7 11 
 Elevated SGOT (AST)  1 2 5 8 
 Elevated Bilirubin  <1 1 5 8 
 Elevated Creatinine  0 2 1 1 
CTC grades: neutropenia (Grade 3 ≥0.5–1.0 × 109/L, Grade 4 <0.5 × 109/L); thrombocytopenia (Grade 3 ≥10–50 × 
109/L, Grade 4 <10 × 109/L); anemia (hemoglobin ≥65–80 g/L, Grade 4 <65 g/L); elevated creatinine (Grade 3 >3– 6 
× upper limit normal range (ULN), Grade 4 >6 × ULN); elevated bilirubin (Grade 3 >3–10 × ULN, Grade 4 >10 × 
ULN); elevated SGOT or SGPT (Grade 3 >5–20 × ULN, Grade 4 >20 × ULN); hypocalcemia (Grade 3 <7.0–6.0 
mg/dL, Grade 4 <6.0 mg/dL); hypophosphatemia (Grade 3 <2.0–1.0 mg/dL, Grade 4 <1.0 mg/dL).  
 
4.3.6 L aboratory Abnormalities 
Myelosuppression was commonly reported in all patient populations. The frequency of Grade 3 
or
 4 neutropenia, thrombocytopenia, and anemia was higher in patients with advanced CML o r 
Ph+ ALL than in chronic phase CML. Myelosuppression was reported in patients with normal 
baseline laboratory values as well as in patients with pre-existing laboratory abnormalities. 
(Table 3) 
In patients who experienced severe myelosuppression, recovery generally occurred following 
dose interruption and/or reduction; permanent discontinuation of treatment occurred in 1% of 
patients.  
Grade 3 or 4 elevations of transaminases or bilirubin and Grade 3 or 4 hypocalcemia and 
hypophosphatemia were reported in patients with all phases of CML but were reported with an 
increased frequency in patients with myeloid or lymphoid blast CML and Ph+ ALL. Elevations 
in t
ransaminases or bilirubin were usually managed with dose reduction or interruption.  Patients 
developing Grade 3 or 4 hypocalcemia during the course of dasatinib therapy often had recovery 
with oral calcium supplementation ( Table 3). 
4.3.7 Anticipa ted Adverse Events (Dasatinib) 
4.3.7.1 Myelosuppression 
Treatment with dasatinib is associated with severe (NCI CTC Grade 3 or 4) thrombocytopenia, 
ne
utropenia, and anemia. Their occurrence is more frequent in patients with advanced CML or 
Ph+ ALL than in chronic phase CML. Complete blood counts should be performed weekly for 
the f
irst month and then monthly thereafter, or as clinically indicated. Myelosuppression was 
generally reversible and usually managed by withholding dasatinib temporarily or dose reduction 
(14).  
4.3.7.2 Bleeding Related Events  
In addition to causing thrombocytopenia in human patients, dasatinib caused platelet dysfunction 
 
UPCI 12-048 22 02-15-2016 in vitr
o. Severe CNS hemorrhages, including fatalities, occurred in 1% of patients receiving 
dasatinib. Severe gastrointestinal hemorrhage occurred in 7% of patients and generally required 
treatment interruptions and transfusions. Other cases of severe hemorrhage occurred in 4% of 
patients. Most bleeding events were associated with severe thrombocytopenia.  
Patients were excluded from participation in dasatinib clinical studies if they took medications 
that inhibit platelet function or anticoagulants. Caution should be exercised if patients are 
required to take medications that inhibit platelet function or anticoagulants.  
4.3.7.3 Fluid Retention 
Dasatinib is associated with fluid retention, which was severe in 9% of patients, including pleural 
and pericardial effusion reported in 5% and 1% of patients, respectively. Severe ascites and 
g
eneralized edema were each reported in 1%. Severe pulmonary edema was reported in 1% of 
patients. Patients who develop symptoms suggestive of pleural effusion such as dyspnea or dry 
cough should be evaluated by chest X-ray. Severe pleural effusion may require thoracentesis and 
ox
ygen therapy. Fluid retention events were typically managed by supportive care measures that 
include diuretics or short courses of steroids (14).  
4.3.7.4
 QT Prolongation 
In vitro  data suggest that dasatinib has the potential to prolong cardiac ventricular repolarization 
(Q
T interval). In single-arm clinical studies in patients with leukemia treated with dasatinib, the 
mean QTc interval changes from baseline using Fridericia’s method (QTcF) were 3–6 msec; the 
uppe
r 95% confidence intervals for all mean changes from baseline were <8 msec. Nine patients 
ha
d QTc prolongation reported as an adverse event. Three patients (<1%) experienced a QTcF 
>
500 msec.  
Dasatinib should be administered with caution to patients who have or may develop prolongation 
of QTc.  These include patients with hypokalemia or hypomagnesemia, patients with congenital 
long QT syndrome, patients taking anti-arrhythmic medicines or other medicinal products that 
lead to QT prolongation, and cumulative high-dose anthracycline therapy. Hypokalemia or 
hypomagnesemia should be corrected prior to dasatinib administration (14).  
5. S TUDY TREATMENT PLAN 
No investigational or commercial agents or therapies other than those described below may be 
administered with the intent to treat the patient's malignancy. 
5.1 Dasat inib Administration 
All 
patients will receive dasatinib at a star ting dose of 70 mg twice daily by mouth in the 
outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of 
the 50 mg
 tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the 
sa
me time each day. Dasatinib may be taken with or without food. Patients are to swallow the 
 
UPCI 12-048 23 02-15-2016 table
ts whole. The tablets should not be cut, crushed or dissolved. Study medication will be self-
administered and patients will be asked to keep a daily diary of the time and dose of drug 
ingested. 
Patients on Arm A will start dasatinib administration on cycle 2, day 1 (week 5), while those 
patients in Arm B will start dasatinib administration on cycle 1, day 1 (week 1). Study treatment 
will continue for at least 6 cycles or disease progression.  In case of vaccine depletion patients 
may continue on dasatinib alone and there is evidence of clinical benefit. 
The
 dosing time may be adjusted as required for subject convenience. If doses are missed for 
toxicity, they should not be replaced. If a dose is not taken due to an error, it may be taken up to 
12 hours later. If vomiting occurs within 30 minutes of intake, that dose may be repeated. 
Patients will be provided with a diary in which to record any changes in dosing of study drug. 
Da
satinib should not be taken with grapefruit containing food or beverages. 
REGIMEN DESCRIPTION  
Agent  Premedications /
Precautions  Dose  Route  Schedule  Cycle 
Length  
αDC1  Vaccine  None  107 cells Intradermal 
injection  Arms A and B: every 2 weeks 
starting on Cycle 1, day1  
28 days  
(4 weeks)  Dasatinib  Take with or 
without food  70 mg  Orally, 
twice a day  Arm A: Daily  starting on 
Cycle 2, day 1  
Arm B: daily starting on Cycle 
1, day 1  
 
5.2 Vac cine administration 
The DC vaccine will be administered by a single intradermal injection of approximately 107 c ells 
(a minimum of 5 x 106 cells is allowable due to manufacturing limitations), with all the DCs 
be
ing administered on days 1and 15 of each cycle. The intradermal administration will be in the 
vicinit
y of the four nodal drainage groups of the four extremities and performed on an outpatient 
ba
sis in the UPCI-CTRC. Study treatment will continue for at least 6 cycles or disease 
progression. 
5.3 Durat ion of Study Treatment 
In the absence of treatment delays due to adverse event s, treatment may continue for at least 6 
c
ycles until one of the following criteria applies: 
 Disease progression, 
 Intercurrent illness that prevents further administration of treatment, 
 Unacceptable adverse event(s), 
 
UPCI 12-048 24 02-15-2016  P
atient decides to withdraw from the study, or 
 Ge
neral or specific changes in the patient's condition render the patient unacceptable for 
further treatment in the judgment of the investigator/sub-investigator. 
 S
tudy is terminated 
 Loss of ability to freely provide consent 
Patients may continue on dasatinib alone in case the vaccine product is no longer available and 
there is evidence of clinical benefit. 
5.4 Durat ion of Follow Up 
Patients will be followed for 1 year (+2 months) per standard of care visits or through medical 
records review after removal from study treatment or until death, whichever occurs first. Patients 
removed from study for unacceptable adverse event(s) will be followed until resolution or 
stabilization of the adverse event. 
6. S TUDY CALENDAR 
Schedules shown in the Study Calendar below are provided as an example and should be 
modified as appropriate. 
 
Screening evaluations are to be conducted within 1 week of leukapheresis. Scans and x-rays 
must
 be done < 4 weeks prior to baseline. In the event that the patient’s condition i s 
deteriorating, laboratory evaluations should be repeated within 48 hours prior to initiation of the 
next cycle of therapy. 
Week  Up to -1d 
from 
baseline  Baseline  1 2 3 4 5e 6e 7e 8e Off Study  
Treatmentf 
Informed consent  X           
HLA -A2 Screeninga X           
BRAF, c -KIT mutationa X           
Demographics  X           
Medical history  X           
Physical exam  X  X  X  X  X  X 
Vital signs  X  X  X  X  X  X 
Height  X           
Weight  X  X  X  X  X  X 
Performance status  X  X  X  X  X  X 
CBC w/diff, platelets  X  X X X X X X X X X 
Serum chemistryb X  X X X X X X X X X 
B-HCGc X           
EKG (as indicated)  X           
Leukapheresis   Xi          
 
UPCI 12-048 25 02-15-2016 Week  Up to -1d 
from 
baseline  Baseline  1 2 3 4 5e 6e 7e 8e Off Study  
Treatmentf 
Vaccine production   X          
Dasatinib  
Arm A  
Arm B     
 
X  
 
X  
 
X  
 
X  
X 
X  
X 
X  
X 
X  
X 
X  
DC Vaccinee   X  X  X  X   
Immune monitoring -PBMC  Xg  X  X  X  X 
Tumor Biopsy  Xg    X     
AE evaluation    X X 
Tumor measurements  X  Tumor measurements are repeated every 8 weeks . 
Documentation (radiologic) must be provided for 
patients removed from study for progressive disease.  X 
Radiologic evaluation  X  Radiologic measurements should be performed every 
8 weeks.  Xh 
a: Not necessary if already known.  
b: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, 
phosphorus, potassium, total protein, SGOT [AST], SGPT [ALT], sodium, magnesium.  
c: Serum pregnancy test (women of childbearing potential).  
d: Screening is to be performed in the UPCI -CTRC.  
e: Treatment with DC vaccine and dasatinib will continue for at least  6 cycles  (or until disease progression) , the weeks of 
those cycles will follow the tests and procedures listed for weeks 5 through 8 above for each subsequent cycle.  
f: Four weeks after the last dasatinib administration.  
g: Can happen at any time prior to start of study treatment.  
h: If removed from the study for reasons other than DP . 
i: Additional leukapheresis procedures may be performed at the discretion of the Investigator/sub -investigator for patients 
that derive benefit but require productio n of additional vaccine.  
 
There is a window of ±7 calendar days available for scheduling/rescheduling treatment and/or procedures at the discretion of 
the Sub -investigator, and as discussed with the Investigator if a course is missed or a subject's treatme nt and/or testing day(s) 
need to be rescheduled due to the subject’s inability to comply with the study calendar (this includes but is not limited to:  
hospitalizations, business, vacation plans, travel from long distances for study treatment, in advance of  the scheduled date to 
allow ready access to the result(s), reduce financial burden on the subject [i.e. non -UPMC insurance coverage] or reduce 
travel inconvenience, illness, transportation issues, holidays, family emergencies, etc.).  
 
7. DOS E-LIMITING TOXICITIES 
7.1 De finition of Dose-Limiting Toxicity 
Toxicities will be scored according to the NCI Common Terminology Criteria for Adverse 
Events (NCI CTCAE) v4.0. 
Dose
-limiting toxicity (DLT) is defined as the following regimen-related events experienced 
during Cycle 1 and 2 for Arm A and during Cycle 1 for Arm B: 
 Grade 4 neutropenia or thrombocytopenia which lasts more than 7 days; 
 Grade 3 or 4 febrile neutropenia; or 
 Grade 3 or greater non-hematological toxicities; this includes grade 3 or greater diarrhea, 
nausea or vomiting which last more than 7 days despite adequate treatment (with 
loperamide for diarrhea, 5HT3 antagonists, steroids and dopamine antagonist for N/V). 
 
UPCI 12-048 26 02-15-2016  
7.2 Dasat inib Dosing delays/modifications 
Dose Level  Dasatinib  Dose 
0 70 mg twice a day  
-1 50 mg twice a day  
-2 100 mg once a day  
 
This study will use the CTCAE (Common Terminology Criteria for Adverse Events) version 4.0 
for toxicity and serious adverse event reporting. A copy can be downloaded from the CTEP 
homepage http://ctep.cancer.gov. 
7.2.1 Gr ades 1 or 2 hematologic or non-hematologic toxicities 
No routine dose interruptions or reductions will occur for Grades 1 or 2 toxicities. If the subject 
experiences an intolerable Grade 2 toxicity, dasatinib may be reduced 1 dose level without 
temporarily withholding study drug. If the toxicity resolves to baseline, dasatinib may be 
escalated to the previous dose level. If the intolerable toxicity recurs after re-escalation, dasatinib 
should be reduced 1 dose level and re-escalation of dose should not occur. 
7.2.2 Gr ades 3 or 4 hematologic or non-hematologic toxicities 
If the subject experiences a clinically significant Grade 3 non-hematologic toxicity or any Grade 
4 non -hematologic toxicity or Grade 3 or 4 neutropenia or thrombocytopenia, dasatinib must be 
withheld until the toxicity resolves to Grade 1 or less or returns to baseline at the start of therapy, 
and the dose must be reduced 1 dose level when drug is restarted. If the clinically significant 
Grade 3, or Grade 4 non-hematologic toxicity, or Grade 3 or 4 neutropenia or thrombocytopenia 
re
curs on the lower dose of dasatinib, drug must be withheld until the toxicity resolves to Grade 
1 or less or returns to baseline, and the dose must be reduced to level -2 when restarted. If the 
clinically significant Grade 3, or Grade 4 non-hematologic toxicity, or Grade 3 or 4 neutropenia 
or thrombocytopenia recurs on dose level -2 of dasatinib, the subject’s treatment with dasatinib 
will be discontinued but follow-up for tumor progression and survival will continue. 
7.3 Vac cine Dosing delays/modifications 
Although past experience at UPCI and other clinical centers performing DC-based vaccinations 
suggests that immunization with DC1-based vaccines will be well-tolerated and have little if any 
serious adverse side effects, to ensure patient safety we will closely monitor for any potential 
a
utoimmunity. No dose modifications will be allowed. 
8. PATIENT SELECTION 
8.1 Inclusion Criteria 
 P
atients must be HLA- A2+ and have histologically confirmed melanoma that is 
metastatic (Stage IV) or unresectable Stage IIIB/C and for which standard curative or 
palliative measures do not exist or are no longer effective. 
 
UPCI 12-048 27 02-15-2016  P
atients must have measurable disease by RECIST 1.1, defined as at least one lesion that 
can be accurately measured in at least one dimension (longest diameter to be recorded for 
non-nodal lesions and short axis for nodal lesions) as > 20 mm with conventional 
techniques or as > 10 mm with spiral CT scan, MRI, or calipers by clinical exam. See 
Section 11 for the evaluation of measurable disease. 
 Patients should have at least 2 subcutaneous, intracutaneous, and accessible tumor 
deposits, lymph node or other site available for biopsy purposes. Patients that have one 
biops
iable site that can be amenable to 2 biopsies (pre- and post-) will be considered 
e
ligible. 
 Prior chemotherapy, immunotherapy, or targeted therapy is allowed as long as it did not 
include dasatinib. 
 Age
 > 18 years. B ecause no dosing or adverse event data are currently available on the 
use of dasatinib  in patients < 18 years of age, children are excluded from this study, but 
will
 be eligible for future pediatric trials. 
 ECOG performance status < 2 (Karnofsky > 60%, see App endix A ). 
 Life expectancy of greater than  12 weeks. 
 Patients must have normal organ and marrow function as defined below: 
o L eukocytes ≥ 3,000/µL 
o a bsolute neutrophil count ≥ 1,500/µL 
o a bsolute lymphocyte count ≥ 500/µL 
o plate lets ≥ 100,000/µL 
o tot al bilirubin within normal institutional limits 
o AST(SGOT) /ALT(SGPT) ≤ 2.5 X institutional upper limit of normal 
o C reatinine  ≤ 2.0 X institutional upper limit of normal 
 Serum magnesium, potassium and adjusted (or ionized) calcium ≥ the institutional lower 
li
mit of normal. (Supplementation of electrolytes prior to screening is allowed). 
 Sexually active women and men of childbearing potential must agree to use an effective 
method of
 birth control during the course of the study and for up to 3 months following 
the last dose of the study drug, in a manner such that risk of pregnancy is minimized. 
Surgical sterilization, intrauterine device, birth control pills, or barrier method (e.g. 
c
ondom and/or diaphragm with spermicidal agents) are acceptable forms of birth control. 
Women of childbearing potential must have a negative pregnancy test (serum) within 7 
days prior to treatment. A pregnancy test is not required for registration. Women who 
have not menstruated for more than 2 years will be considered postmenopausal, thus not 
of childbearing potential. 
 Ability to understand and the willingness to sign a written informed consent document.  
8.2 E xclusion Criteria 
 Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for 
nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered 
from adverse events due to agents administered more than 4 weeks earlier. 
 Patients with documented c-KIT mutations. 
 Patients who are receiving any other investigational agents. 
 Patients with known active brain metastases should be excluded. Patients with treated 
brain metastases with documented stability for 4 weeks are eligible. 
 
UPCI 12-048 28 02-15-2016  Hist
ory of allergic reactions attributed to compounds of similar chemical or biologic 
composition to dasatinib or any of the components of the vaccine being administered as 
part of this study. 
 Women who are pregnant or nursing/breastfeeding. 
 History of significant bleeding disorder unrelated to cancer, including: 
o Dia gnosed congenital bleeding disorders (e.g., von Willebrand’s disease) 
o Dia gnosed acquired bleeding disorder within one year (e.g., acquired anti-factor 
VIII antibodies) 
 Patients currently taking medications that inhibit platelet function (i.e., aspirin, 
dip
yridamole, epoprostenol, eptifibatide, clopidogrel, cilostazol, abciximab, ticlopidine, 
and any non-steroidal anti-inflammatory drug) because of a potential increased risk of 
bleeding from dasatinib. 
 Patients currently taking anticoagulants (warfarin, heparin/low molecular weight heparin 
[
e.g., danaparoid, dalteparin, tinzaparin, enoxaparin]) because of a potential increased 
risk of bleeding from dasatinib. 
 Diagnosis of unstable angina or myocardial infarction within 6 months of study entry. 
 Patients currently taking one or more of the following drugs that are generally accepted to 
ha
ve a risk of causing Torsades de Pointes: 
o quini dine, procainamide, disopyramide 
o a miodarone, sotalol, ibutilide, dofetilide 
o e rythromycins, clarithromycin 
o c hlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide 
o c isapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, 
halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine. 
 Diagnosed or suspected congenital long QT syndrome. 
 Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec) within 30 days prior 
to study registration. 
 Any history of clinically significant ventricular arrhythmias (such as ventricular 
tachycardia, ventricular fibrillation, or Torsades de pointes) 
 Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, 
symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or 
psychiatric illness/social situations that would limit compliance with study requirements. 
 HIV-positive patients on combination antiretroviral therapy are ineligible because of the 
potential for pharmacokinetic interactions with dasatinib. In addition, these patients are at 
increased risk of lethal infections when treated with marrow-suppressive therapy. 
Appropriate studies will be undertaken in patients receiving combination antiretroviral 
therapy when indicated. 
 
8.3 In clusion of Women and Minorities 
Both men and women of all races and ethnic groups are eligible for this trial. 
8.4 General Concomitant Medication and Supportive Care Guidelines 
In general, concomitant medications and therapies deemed necessary for the supportive care and 
safety of the patient are allowed. The administration of growth factors (e.g. procrit, neupogen) is 
 
UPCI 12-048 29 02-15-2016 a
llowed. ASCO guidelines for providing growth factor support are recommended. The 
administration of any other anticancer agents including chemotherapy and biologic agents is not 
permitted. The administration of interferons is not allowed. The use of other concurrent 
investigational drugs is not allowed. 
8.4.1 B isphosphonates 
Intravenous bisphophonates will be withheld for the first 8 weeks of treatment due to the risk of 
hypocalcemia. After the need for Ca2+ supplementation has been assessed and levels documented 
to be >
 lower limit of normal, patients on prior bisphosphonate may be restarted with caution at 
the inve
stigator’s discretion. 
8.4.2 Anta cids 
Short-acting antacid agents may be taken, but it is recommended that these not be taken from 2 
hours be
fore to 2 hours after dosing of dasatinib. In vitro  solubility data indicate that dasatinib 
ma
y have decreased solubility and absorption at pH > 4. Until further data are available, patients 
shoul
d try to avoid taking proton pump inhibitors and H2 antagonists. 
8.4.3 Medic ations that prolong the QT interval 
Ideally, patients should not take medications known to prolong the QT interval. However, should 
the Investigator believe that beginning therapy with a potentially QT prolonging medication 
(other than the ones explicitly prohibited) is vital to an individual subject’s care, the Investigator 
must check that the subject’s prior on-therapy ECG has not shown a QTcF  480 msec or an 
incr
ease in QTc  60 msec over the baseline value. Additional ECG(s) will be done one week 
late
r or more at the Investigator’s discretion to ensure the subject’s safety. 
8.4.4 Medic ations that affect CYP3A4 
Caution is warranted when administering dasatinib to patients taking drugs that are highly 
de
pendent on CYP3A4 for metabolism and have a narrow therapeutic index. Systemic exposures 
to these medications could be increased while receiving dasatinib. In in vitro  studies, dasatinib is 
a
 strong inhibitor of the human CYP3A4 enzyme and a weak inhibitor of CYP1A2, CYP2D6 and 
CYP2C19. Dasatinib shows time-dependent inhibition of CYP3A4; however, there appears to be 
a low probability for drug-drug interactions due to metabolism-dependent CYP3A4 inactivation. 
Results from an in vitro  hPXR trans-activation study suggest that dasatinib has little potential to 
induce
 CYP3A4 through the activation of hPXR. 
Until information regarding exposure-toxicity and exposure-response relationships is available 
with dasatinib, concomitant CYP3A4 inhibitors and inducers should be avoided since they could 
alter the systemic exposure to dasatinib. Incubations with recombinant human CYP450 isozymes 
suggest that dasatinib is primarily metabolized by the CYP3A4 enzyme. Many other enzymes 
appear capable of metabolizing dasatinib, including CYP1A1, 2C9, 2E1, FMO3, 1B1, 2B6, 2A6, 
2C8, and 4A1; however, it is unknown at this time what contributions these enzymes may have 
 
UPCI 12-048 30 02-15-2016 to t
he total metabolic clearance of dasatinib. 
Based on pre-clinical data, dasatinib may increase the likelihood of bleeding. Hence, patients 
unde
rgoing surgical procedures, including dental procedures, should be instructed to inform their 
doctors of this potential increased risk. Patients requiring surgery should stop dasatinib at least 1 
da
y prior to surgery, when feasible. As dasatinib has the potential to cause hemorrhage and its 
effect on wound healing is unclear, a minimum 2 week wait time after surgery is recommended 
and further do not resume medication until recommended by the attending surgeon based on the 
post-operative course. 
Palliative radiation is allowed provided that the irradiated lesion is not the sole target lesion for 
response assessment. 
The following medications are prohibited: 
 St. John's wort (Hypericum perforatum): May decrease dasatinib plasma concentrations 
unpredictably. Patients receiving dasatinib should not take St. John's wort. 
 H2 B
lockers/Proton Pump Inhibitors:  Long-term suppression of gastric acid secretion by 
H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to 
reduce dasatinib exposure. The concomitant use of H2 blockers or proton pump inhibitors 
with dasatinib is not recommended. The use of antacids should be considered in place of 
H2 blockers or proton pump inhibitors in patients receiving dasatinib therapy (see Section 
5.2.2 , antacids).   
9. RES EARCH SAMPLES 
Patient peripheral blood and tumor biopsies will be obtained at various time points prior to, and 
after, the initiation of therapy. 
If the patient is determined to express the HLA-A2 antigen on their peripheral blood cells, to 
express a wild-type phenotype, and they pass all additional inclusion/exclusion criteria, after 
written consent, they may be entered on trial. 
Those patients determined to express c-KIT mutations will be excluded from study, while BRAF 
mutational status will be used to stratify patients during randomization to ensure a balanced 
proportion of patients with the mutation on both arms. 
9.1 Biopsy tissue 
Melanoma biopsies will be obtained prior to the first vaccination (baseline) and week 5  (date of 
the third vaccination). Patients should have at least 2 subcutaneous, intracutaneous, and 
accessible tumor deposits, lymph node or other site available for biopsy purposes or one 
biops
iable site that can be amenable to 2 biopsies (pre- and post-) will be considered eligible. 
  
 
UPCI 12-048 31 02-15-2016 9.2 B lood samples 
At least 3 weeks prior to study treatment, peripheral blood will be obtained for the screening of 
patient HLA-A2 expression status (if not already known) and for baseline testing. Peripheral 
blood will be obta
ined every 2 weeks on trial beginning Cycle 1 week 3. 
10. CORR ELATIVE STUDIES 
We expect to observe that HLA-A2/TBVA peptide dextramer+ CD8+ T cells (i.e. CD8+ T cells 
imaged by flow cytometry using a fluorescently-labeled, antigen-specific probe) will exhibit 
hig
her frequencies in the peripheral blood and a greater propensity to produce IFN-  after the 
initiation of DC1-based vaccines. Since dasatinib is expected to alter the recruiting capacity of 
the tumor microenvironment based on activation of VCAM-1 expression on the tumor-associated 
vascular endothelial cells and locoregional production of CXCR3 ligand chemokines, it is very 
possible (and likely clinically-preferred) that the frequency of TBVA-specific CD8+ T cells will 
se
lectively decline in the patients peripheral blood if the combined therapy is performing as 
expected based on our preclinical modeling data (given recruitment away out of the blood and 
into the tumor le
sion). Based on a recent publication by Ernstoff and colleagues (99), circulating 
leve
ls of the CXCR3 ligand CXCL10 (aka IP- 10), as well as, the Okada and colleagues Phase 
1/2 trial results for DC1 /peptide vaccination of glioma patients (88 ) may become elevated 
under treatment conditions in patients that are more prone to exhibit objective clinical response 
to effective immunotherapy. As a consequence, we will analyze levels of serum CXCL10 before, 
during
 and after combined vaccine + dasatinib therapy to determine correlation with TBVA-
specific CD8+ T cells in the blood versus tumor over time post-treatment. 
10.1 Imm une Monitoring Analysis of TBVA-specific CD8+ T cell responses (Primary 
E
ndpoint). 
Rationale and Hypothesis : Translation and clinical vaccine trials have demonstrated that 
DC/peptide-based vaccines effectively activate specific CD8+ T cells in tumor-bearing hosts that 
may be detected in peripheral blood, and that individuals that exhibit objective clinical response 
to such vaccine therapies tend to derive from the cohort of patients that display detectable 
increases in T cell responses post-vaccination (25-27). Our own pre-clinical studies support the 
e
ffectiveness of DC1/peptide vaccination to elicit protective/therapeutic T cell-mediated 
immunity in melanoma models in vivo (49), supporting the hypothesis that DC1/ peptide 
vaccination of advanced stage melanoma patients will result in increased quantities of specific 
CD8+ T cells in patient peripheral blood and that those individuals in which improved response 
to many peptides can be observed are those that are more likely to demonstrate clinical benefit.  
Method:  Using fluorescently-labeled HLA-A2/peptide dextramer probes and intracellular 
staini
ng for the Type-1 cytokine IFN- , we can simultaneously determine how the frequency of 
CD8+ T cells specific for TBVA peptides changes over time post-vaccination and how many of 
 
UPCI 12-048 32 02-15-2016 these
 T cells are Type-1 effector T cells. By screening for in vitro  reactivity of T cells against 
mela
noma antigen-derived peptides, we will also be able to assess how vascular-targeting T cell 
responses may promote the corollary ability of the immune system to recognize melanoma-
associated peptide epitopes (i.e. “epitope spreading”) that is hypothesized by many to be a strong 
surrogate for the clinical efficacy of immunotherapeutic approaches (25-27).  
10.2 Qu antitation of CD8+ T cells, Treg, MDSC and blood vessels in melanoma biopsy 
tissue  
Ratio
nale and Hypothesis : Tumor progression is believed to be linked to the accumulation of 
suppressor cell populations (both MDSC and Treg) and strong pro-angiogenic signals, as well as, 
“prevention” of Type-1 T cell recruitment within the tumor microenvironment (65-74). Our 
preliminary data in murine melanoma models support the ability of dasatinib (particularly when 
combined with DC1/peptide vaccines) to counteract these biologic endpoints in vivo  (F igs. 1, 3 ). 
We hypothesize that such changes may also be evidenced in effectively treated melanoma 
patients by analyzing melanoma biopsies taken post- versus pre-treatment and that the greatest 
“normalization” of the tumor microenvironment will be observed after treatment with combined 
dasatinib + vaccine therapy.  
Method:  Immunofluorescence microscopy will be used to analyze tumor sections of melanoma 
biopsies for expression of the markers CD8 (T effector cells), CD11b + C D33 + lack of HLA-
DR 
(lineage-negative MDSC), CD11b + CD15 + lack of CD14 (neutrophilic MDSC), CD11b + 
C
D14 + lack of CD15 (myeloid MDSC), CD4 + Foxp3 (Treg cells) and CD31 + NG2 (blood 
ve
ssels). After staining and washing, sections will be covered in Gelvatol (Monsanto, St. Louis, 
MO) and a coverslip applied. Positively-stained cells will be quantitated by analyzing the images 
a
t a final magnification of x20 using Metamorph Imaging software (Molecular Devices, 
Sunnyvale, CA). 
10.3 Tr eg analysis in PBMC 
Rationale and Hypothesis : Cancer patients have commonly also been shown to have elevated 
populational frequencies of Treg (based on the CD4+Foxp3+ phenotype) circulating in the 
pe
ripheral blood. Alternate TKI, such as sunitinib, have been shown capable of reducing 
pe
ripheral blood Treg levels within the first 4 week cycle of drug administration, in concert with 
a rebound in Type-1 T cell numbers and function in PBMC (59). Based on our pre-clinical data 
(Fig. 1 ), we hypothesize that dasatinib with provide a similar effect in melanoma patients and 
that those patients exhibiting the greatest degree of Treg reduction post-therapy will be more 
likely to respond favorably against the peptide epitopes contained in the vaccine formulation.  
M
ethod:  Peripheral blood cells will be analyzed by flow cytometry using specific antibodies 
a
gainst CD3 (all T cells), CD4 + Foxp3 (Treg), CD4 + CD25hi (Treg) Results will expressed as 
percentage of CD25+hi/Foxp3+ cells out of total CD3+/C D4+ viable cells.  
 
UPCI 12-048 33 02-15-2016 10.4 M DSC Analysis in PBMC 
Rationale and Hypothesis : Similar to Treg, levels of cells expressing an MDSC phenotype have 
been reported to be elevated in the peripheral blood of cancer patients, including patients with 
advanced-stage melanoma (60, 61). TKI, such as sunitinib and dasatinib can reduce the 
fr
equency of such suppressor cells to a variable degree when used as a therapy (ref. 60, Fig. 1 ). 
We hypothesize that melanoma patients treated with dasatinib will exhibit reduction in MDSC 
frequencies in PBMC, with the degree of loss correlating with the patient’s ability to respond 
fa
vorably against the peptide epitopes contained in the vaccine formulation.  
Method:  Analysis of MDSC percentages in patient PBMC will be performed using flow 
cytometry and anti-human antibodies against CD11b, CD11c, CD14, CD15, CD33 and HLA- DR 
a
s previously described (100).  
10.5 E phA2 Protein Levels in tumor biopsies 
Rationale and Hypothesis : We have previously shown that drug treatments (including dasatinib 
in vitro ) that promote the proteasome-dependent degradation of the tumor (and tumor vascular 
endothelial) cell-associated protein EphA2 lead to improved recognition by specific CD8+ T cells 
(r
efs. 101, 102 and Fig. 2 ). We hypothesize that administration of dasatinib to melanoma patients 
will promote the loss of EphA2 protein within the tumor lesion, leading to an enhancement in the 
se
nsitivity of EphA2+ cells in the tumor microenvironment to EphA2-specific CD8+ T cells that 
have been activated as a consequence of DC1/peptide-based vaccination.  
M
ethod:  Western blotting and immunofluorescence microscopy will be used to quantitate EphA2 
pr
otein expression in melanoma biopsies pre- versus post-vaccination.  
10.6 CX CL10 Levels in Patient Serum  
Rationale and Hypothesis : We and others have recently shown that therapeutic CD8+ T cells 
re
quire the production of CXCR3 ligand chemokines within the tumor microenvironment in 
order to effectively home to these disease sites. Two recent clinical trials, including our 
DC1/glioma peptide vaccination trial in patients with brain tumors strongly support CXCL10 
(aka IP-10) as a chemokine associated with superior clinical outcome to immune-based therapy 
(88, 9
9). We hypothesize that this will also be the case in our DC1/TBVA peptide vaccinated 
patients with melanoma where Type-1 CXCR3+ responder T cells require a gradient of 
CXCL10/IP-10 (as detected in serum) in order to traffick to tumor sites in vivo .  
Method: Patient serum levels of CXCL10 will be monitored using Luminex fluorescent bead 
technology according to manufacturer's protocol. 
11. M EASUREMENT OF EFFECT 
Although objective tumor response is not the primary endpoint of this trial, patients with 
measurable disease will be assessed by standard criteria. For the purposes of this study, patients 
 
UPCI 12-048 34 02-15-2016 shoul
d be re-evaluated every 8 weeks. In addition to a baseline scan, confirmatory scans will also 
be obtained ≥ 4 weeks following initial documentation of an objective response. 
11.1 Antitumor Effect  
For the purposes of this study, patients should be re-evaluated for response every 8 weeks. In 
addition to a baseline scan, confirmatory scans should also be obtained no less than 4 weeks 
following initial documentation of objective response. 
Response and progression will be evaluated in this study using the new international criteria 
proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline 
(version 1.1; ref. 104). Changes in the largest diameter (uni-dimensional measurement) of the 
tum
or lesions and the shortest diameter in the case of malignant lymph nodes are used in the 
RECIST criteria. 
11.1.1 Definitions 
Evaluable for toxicity. All patients will be evaluable for toxicity from the time of their first 
treatment. 
Evaluable for objective response. Only those patients who have measurable disease present at 
baseline, have received at least one cycle of therapy, and have had their disease re-evaluated will 
be considered evaluable for response. These patients will have their response classified 
according to the definitions stated below. (Note:  Patients who exhibit objective disease 
pr
ogression prior to the end of cycle 1 will also be considered evaluable.) 
Evaluable Non-Target Disease Response. Patients who have lesions present at baseline that are 
evaluable but do not meet the definitions of measurable disease, have received at least one cycle 
of therapy, and have had their disease re-evaluated will be considered evaluable for non-target 
disease. The response assessment is based on the presence, absence, or unequivocal progression 
of the lesions.  
11.1.2 Disease Parameters 
Mea
surable disease. Measurable lesions are defined as those that can be accurately measured in 
at least one dimension (longest diameter to be recorded) as > 20 mm by chest x-ray or as > 10 
mm with CT scan, MRI, or calipers by clinical exam. All tumor measurements must be recorded 
in 
millimeters (or decimal fractions of centimeters). 
Note: Tumor lesions that are situated in a previously irradiated area might or might not be 
considered measurable. If the investigator thinks it appropriate to include them, the conditions 
under which such lesions should be considered must be defined in the protocol. 
Malignant lymph nodes. To be considered pathologically enlarged and measurable, a lymph node 
must be > 15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended 
to be no greater than 5 mm). At baseline and in follow-up, only the short axis will be measured 
 
UPCI 12-048 35 02-15-2016 a
nd followed. 
Non-measurable disease . All other lesions (or sites of disease), including small lesions (longest 
diameter < 10 mm or pathological lymph nodes with ≥ 10 to < 15 mm short axis), are considered 
non-measurable disease. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial 
e
ffusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses 
(not followed by CT or MRI), are considered as non-measurable. 
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not 
be considered as malignant lesions (neither measurable nor non-measurable) since they are, by 
de
finition, simple cysts. 
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, 
if they meet the definition of measurability described above. However, if non-cystic lesions are 
present in the same patient, these are preferred for selection as target lesions. 
Target lesions. All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target lesions  and recorded 
and measured at baseline. Target lesions should be selected on the basis of their size (lesions 
with the longest diameter), be representative of all involved organs, but in addition should be 
those that lend themselves to reproducible repeated measurements. It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement in which 
circumstance the next largest lesion which can be measured reproducibly should be selected. A 
sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions wil
l be calculated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then only the short axis is added into the sum. The baseline sum diameters 
will
 be used as reference to further characterize any objective tumor regression in the measurable 
dimension of the disease. 
Non-target lesions. All other lesions (or sites of disease) including any measurable lesions over 
and above the 5 target lesions should be identified as non-target lesions and should also be 
recorded at baseline. Measurements of these lesions are not required, but the presence, absence, 
or
 in rare cases unequivocal progression of each should be noted throughout follow-up.  
11.1.3 Methods for Evaluation of Measurable Disease 
All measurements should be taken and recorded in metric notation using a ruler or calipers. All 
baseline evaluations should be performed as closely as possible to the beginning of treatment and 
never more than 4 weeks before the beginning of the treatment. 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is 
preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be 
 
UPCI 12-048 36 02-15-2016 im
aged but are assessable by clinical exam. 
Clinical lesions. Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and  10 mm diameter as assessed using calipers 
(e.g., skin nodules). In the case of skin lesions, documentation by color photography, including a 
rule
r to estimate the size of the lesion, is recommended. 
C
hest x-ray. L esions on chest x-ray are acceptable as measurable lesions when they are clearly 
defined and surrounded by aerated lung. However, CT is preferable. 
Conventional CT and MRI. This guideline has defined measurability of lesions on CT scan based 
on the assumption that CT slice thickness is 5 mm or less. If CT scans have slice thickness 
greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness. 
MRI is also acceptable in certain situations ( e.g. for body scans).  
Use
 of MRI remains a complex issue. MRI has excellent contrast, spatial, and temporal 
re
solution; however, there are many image acquisition variables involved in MRI, which greatly 
impact image quality, lesion conspicuity, and measurement. Furthermore, the availability of MRI 
is var
iable globally. As with CT, if an MRI is performed, the technical specifications of the 
scanning sequences used should be optimized for the evaluation of the type and site of disease. 
Furthermore, as with CT, the modality used at follow-up should be the same as was used at 
baseline and the lesions should be measured/assessed on the same pulse sequence. It is beyond 
the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameters for all 
scanners, body parts, and diseases. Ideally, the same type of scanner should be used and the 
image acquisition protocol should be followed as closely as possible to prior scans. Body scans 
should be performed with breath-hold scanning techniques, if possible. 
PET- CT. At present, the low dose or attenuation correction CT portion of a combined PET-CT is 
not always of optimal diagnostic CT quality for use with RECIST measurements. However, if 
the site can document that the CT performed as part of a PET-CT is of identical diagnostic 
quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the PET-CT can be 
used for RECIST measurements and can be used interchangeably with conventional CT in 
accurately measuring cancer lesions over time. Note, however, that the PET portion of the CT 
int
roduces additional data which may bias an investigator if it is not routinely or serially 
performed.  
Ultrasound. Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement. Ultrasound examinations cannot be reproduced in their entirety for 
independent review at a later date and, because they are operator dependent, it cannot be 
guaranteed that the same technique and measurements will be taken from one assessment to the 
next. If new lesions are identified by ultrasound in the course of the study, confirmation by CT or 
MR
I is advised. If there is concern about radiation exposure at CT, MRI may be used instead of 
 
UPCI 12-048 37 02-15-2016 C
T in selected instances. 
Endoscopy, Laparoscopy. The utilization of these techniques for objective tumor evaluation is 
not advised. However, such techniques may be useful to confirm complete pathological response 
when biops
ies are obtained or to determine relapse in trials where recurrence following complete 
response (CR) or surgical resection is an endpoint. 
Cytology, Histology. These techniques can be used to differentiate between partial responses 
(PR) and complete responses (CR) in rare cases ( e.g., residual lesions in tumor types, such as 
germ cell tumors, where known residual benign tumors can remain). 
The cytological confirmation of the neoplastic origin of any effusion that appears or worsens 
during treatment when the measurable tumor has met criteria for response or stable disease is 
mandatory to differentiate between response or stable disease (an effusion may be a side effect of 
the treatment) and progressive disease. 
FDG-PET.  While FDG-PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease). New lesions on the basis of FDG-
P
ET imaging can be identified according to the following algorithm: 
 Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD 
based on a new lesion. 
 No FDG-PET at baseline and a positive FDG-PET at follow-up:  If the positive FDG-
PET at follow-up corresponds to a new site of disease confirmed by CT, this is PD. If the 
positive FDG-PET at follow-up is not confirmed as a new site of disease on CT, 
additional follow-up CT  scans are needed to determine if there is truly progression 
oc
curring at that site (if so, the date of PD will be the date of the initial abnormal FDG-
PET scan). If the positive FDG-PET at follow-up corresponds to a pre-existing site of 
disease on CT that is not progressing on the basis of the anatomic images, this is not PD. 
 FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy in 
cases where a residual radiographic abnormality is thought to represent fibrosis or 
scarring. The use of FDG-PET in this circumstance should be prospectively described in 
the protocol and supported by disease-specific medical literature for the indication. 
However, it must be acknowledged that both approaches may lead to false positive CR 
due to limitations of FDG-PET and biopsy resolution/sensitivity. 
Note: A ‘positive’ FDG-PET scan lesion means one which is FDG avid with an uptake greater 
than twice that of the surrounding tissue on the attenuation corrected image.  
  
 
UPCI 12-048 38 02-15-2016 11.1.4
 Response Criteria 
11.1.4.1 Evaluation of Target Lesions 
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to <10 mm. 
Partial Response (PR): At least a 30% decrease in the sum of the diameters of target 
lesions, taking as reference the baseline sum diameters. 
Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an 
absol
ute increase of at least 5 mm. (Note:  the appearance of one or more new lesions is also 
c
onsidered progressions). 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study. 
11.1.4.2 Evaluation of Non-Target Lesions 
Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor 
marker level. All lymph nodes must be non-p athological in size (< 10 mm short axis). 
Note: If tumor markers are initially above the upper normal limit, they must normalize for a 
patient to be considered in complete clinical response. 
Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of 
tumor marker level above the normal limits. 
Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal 
progression  of existing non-target lesions. Unequivocal progression  should not normally trump 
tar
get lesion status. It must be representative of overall disease status change, not a single lesion 
incr
ease.  
Although a clear progression of “non-target” lesions only is exceptional, the opinion of the 
treating physician should prevail in such circumstances, and the progression status should be 
confirmed at a later time by the review panel (or Investigator). 
11.1.4.3 Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for progressive disease the smallest 
measurements recorded since the treatment started). The patient's best response assignment will 
depend on the achievement of both measurement and confirmation criteria. 
  
 
UPCI 12-048 39 02-15-2016 F
or Patients with Measurable Disease ( i.e., Target Disease) 
Target 
Lesions  Non-Target 
Lesions  New 
Lesions  Overall 
Response  Best Overall Response when Confirmation is 
Required*  
CR CR No CR ≥4 wks. Confirmation**  
CR Non-CR/Non -PD No PR 
≥4 wks. Confirmation**  CR Not evaluated  No PR 
PR Non-CR/Non -PD/ 
not evaluated  No PR 
SD Non-CR/Non -
PD/not evaluated  No SD Documented at least once ≥4 wks. from 
baseline**  
PD Any Yes or No  PD 
no prior SD, PR or CR  Any PD***  Yes or No  PD 
Any Any Yes PD 
* See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.  
** Only for non -randomized trials with response as primary endpoint.  
*** In exceptional circumstances, unequivocal progression in non -target lesions may be accepted as disease 
progression.  
 
Note : Patients with a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should be reported as “ symptomatic 
deterioration.”   Every effort should be made to document the objective progression even after 
discontinuation of treatment.  
 
For Patients with Non-Measurable Disease ( i.e., Non-Target Disease) 
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Non-CR/non -PD* 
Not all evaluated  No not evaluated  
Unequivocal PD  Yes or No  PD 
Any Yes PD 
*  ‘Non -CR/non -PD’ is preferred over ‘stable disease’ for non -target disease since SD is 
increasingly used as an endpoint for assessment of efficacy in some trials  so to assign 
this category when no lesions can be measured is not advised  
 
11.1.5 Duration of Response  
Duration of overall response: The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date that 
recurrent or progressive disease is objectively documented (taking as reference for progressive 
disease the smallest measurements recorded since the treatment started). 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that progressive disease is objectively documented.   
Duration of stable disease: Stable disease is measured from the start of the treatment until the 
criteria for progression are met, taking as reference the smallest measurements recorded since the 
treatment started, including the baseline measurements.  
  
 
UPCI 12-048 40 02-15-2016 11.1.6
 Progression-Free Survival  
Progression-free survival (PFS) is defined as the duration of time from start of treatment to time 
of progression or death, whichever occurs first. 
12. S TATISTICAL CONSIDERATIONS 
12.1 S tudy Design 
The primary objective of this study is to evaluate the effects of combination therapy of dasatinib 
and vaccine on immune response rate. Here a patient who responded to at last 3 of the 6 peptides 
is considered to have a positive immune response. The secondary objectives of this trial include 
evaluation of clinical response rate, overall survival (OS), progression free survival (PFS), and 
immunological endpoints, which include number of CD8+ T cells, MDSC/Treg regulatory cells 
a
nd blood vessels in tumor lesions, level of EphA2 protein expressed within the tumor lesion and 
the level of the CXCL10/IP-10 chemokine in patient serum pre- versus post-treatment.  
We
 expect that the proportion of patients that are not evaluable for immune endpoint will be 10% 
or less. To ensure a total of 28 evaluable patients, up to 31 evaluable patients will be randomized 
in 1:
1 ratio to receive either: 
A. Vaccine alone starting in the first 28-day cycle followed by vaccine combined with daily 
dasatinib starting on the first day of the second cycle (Arm A) 
B. Va
ccine combined with daily dasatinib starting on the first day of cycle 1 (Arm B) 
The UPCI randomizer will be used for the randomization. The randomization will be stratified 
by BRAF mutation status. 
12.2 S afety Monitoring 
The dose limiting toxicity (DLT) is defined in section 7.2.2. Bayesian analysis will be used to 
c
ontinuously monitor the DLTs in both arm s to ensure that the study will continue enrollment 
without
 interruption as long as the underlying true DLT rate is 20% or less. The posterior 
probability (PPr) will be calculated from the study’s accumulated data on DLTs. A weak prior 
dist
ribution of Beta (0.1, 1.9) was used. If PPr > 0.7, that is, there is a 70% or higher chance that 
more than 20%
 of the patients will experience DLTs, the enrollment of the study arm will stop 
pending a review of both the data and the study’s implementation.  
The following table listed the suspension rule based on the Bayesian analysis calculation.  
Bayesian rule for suspending enrollment  
Suspend accrual if n patients experience a DLT  in N patients treated  
2 2-4 
3 5-9 
4 10-14 
 
The operating characteristics of this study design can be expressed in terms of probability of 
early suspending the enrollment for the combination arm under the assumptions of various the 
 
UPCI 12-048 41 02-15-2016 true
 rates of SAEs. The following table calculated these probabilities based on the simulation of 
10,000 hypothetical trials. 
Frequentist properties of Bayesian rule for suspending enrollment  
Probability of DLT s Probability of suspending the enrollment  Median sample size for the combination arm  
0.05 0.02 14 
0.1 0.09 14 
0.15 0.22 14 
0.2 0.36 14 
0.25 0.53 13 
0.3 0.67 8 
0.35 0.79 7 
0.4 0.88 4 
 
12.3 S ample Size/Accrual Rate 
We estimated an accrual rate of approximately 1-2 patients per month therefore, we the accrual 
will be completed within 20 months. We plan a 12 month follow up after the last patient entered 
the stud
y. Therefore, the study will be completed within 3 2 months after the initiation of the 
study.  
The power calculation for the proposed study is based on the comparison of the positive immune 
response rate between the two treatment arms. Based on a preliminary data of 15 patients, the 
immune response rate for the vaccine only arm is close to 0%. With 14 evaluable patients in each 
arm, we will have 80% power to distinguish a difference between 5% immune response rate (of 
the va
ccine arm) and 50% immune response rate (of the combination arm) with 1-sided Fisher 
exact test ( = 0.025). 
12.4 Dat a Analysis 
12.4.1 Analysis Sets 
Evaluable Patients are patients who meet all of the protocol inclusion/exclusion criteria and 
begin treatment with the protocol assigned regimen. All evaluable patients will be used in the 
analysis of safety, immune response, clinical response, OS and PFS. 
12.4.2 Baseline Characteristics 
Baseline characteristics on all evaluable patients will be provided on demographic variables (age, 
sex, race/ethnicity), performance status, laboratory parameters, prior treatments, and disease 
characteristics, including tumor size, number of nodes involved, and metastatic sites.  
12.4.3 Safety Profile 
NCI CTCAE version 4.0 will be used to evaluate the serious adverse events (SAEs) in each cycle 
of the treatment, and for 30 days beyond the last protocol specified treatment. Sever AEs rate for 
each treatment arm will be calculated and the corresponding exact 95% confidence interval (CI) 
will be provided. All adverse events that are determined to be possibly, probably or definitely 
related to treatment will be tabulated according to grade and type (according to the NCI CTCAE, 
 
UPCI 12-048 42 02-15-2016 Ve
rsion 4.0). For each adverse event category, frequencies will be tabulated by treatment group 
according to the highest grade per patient within 30 days after any study treatment. 
12.4.4 Efficacy Analysis 
The immune response rate, defined as proportion of patients that responded to  3 out of the 6 
pe
ptides, for each study arm will be calculated with 95% exact CI. The clinical response rate for 
e
ach study arm will be estimated by the percentage of patients achieving CR or PR by RECIST 
c
riteria, with corresponding exact 95% CI. Both immune response rate and clinical response rate 
of the two treatment groups will be compared using Fisher exact test. As an exploratory analysis, 
we will also evaluate and compare the immune response for the B-raf mutant carrier and non-
carrier in similar manner as described above.  
The Kaplan-Meier estimate of PFS and OS with corresponding 95% confidence band will be 
provided for each dose level. The corresponding median survival time (with 95% confidence 
limits) will be determined, along with OS and PFS estimates at selected time points. The exact 
log rank test will be used to compare the PFS and OS between the two study arms.  
Exploratory analysis will be conducted to study the association between the positive immune 
re
sponse and:  
a. Objective clinical response. 
b. C D8+ T cell infiltration in tumor after cycle 1. 
c. Reduction in suppressor cells in the tumor and blood.  
d. R eduction in blood vessel density in the tumor after cycle 1. 
e. Reduction in EphA2 protein expression in tumor after cycle 1. 
f. Increased level of the CXCR3 ligand chemokine CXCL 10/IP-10 in patient serum after 
cycle 1.  
Chi-square (or Fisher exact) test will be used to test the association between immune response 
and the categorical outcomes (e.g. objective clinical response). Wilcoxon test will be used to 
compare the continuous outcomes (e.g. CD8+ T cell infiltration, suppressor cell populations, 
tum
or blood vessel density, EphA2 protein expression, chemokine level) between the immune 
re
sponders and non-responders. 
12.5 Re porting and Exclusions 
12.5.1 Evaluation of toxicity 
All patients will be evaluated for toxicity from the time of their first treatment with either 
vaccine alone or dasatinib with vaccine. 
12.5.2 Evaluation of response 
All patients included in the study must be assessed for response to treatment, even if there are 
major protocol treatment deviations or if they are ineligible. Each patient will be assigned one of 
the following categories: 1) complete response, 2) partial response, 3) stable disease, 4) 
 
UPCI 12-048 43 02-15-2016 pr
ogressive disease, 5) early death from malignant disease, 6) early death from toxicity, 7) early 
death because of other cause, or 9) unknown (not assessable, insufficient data). [Note:  By 
a
rbitrary convention, category 9 usually designates the “unknown” status of any type of data in a 
clinical database.] 
All of the patients who met the eligibility criteria (with the possible exception of those who 
received no study medication) should be included in the main analysis of the response rate. 
Patients in response categories 4-9 should be considered to have a treatment failure (disease 
progression). Thus, an incorrect treatment schedule or drug administration does not result in 
exclusion from the analysis of the response rate. Precise definitions for categories 4-9 will be 
protocol specific.  
All conclusions should be based on all eligible patients. Sub-analyses may then be performed on 
the ba
sis of a subset of patients, excluding those for whom major protocol deviations have been 
identified ( e.g., early death due to other reasons, early discontinuation of treatment, major 
pr
otocol violations, etc.) . However, these sub-analyses may not serve as the basis for drawing 
conclusions concerning treatment efficacy, and the reasons for excluding patients from the 
analysis should be clearly reported. The 95% confidence intervals should also be provided. 
13. DA TA SAFETY MONITORING PLAN 
Investigator/Sub-investigators, regulatory, CRS management, clinical research coordinators, 
clinical research associates, data managers, and clinic staff meet monthly in disease center Data 
Safety Monitoring Boards (DSMB) to review and discuss study data to include, but not limited 
to, the following: 
 serious adverse events 
 subject safety issues 
 recruitment issues 
 accrual 
 protocol deviations 
 unanticipated problems 
 breaches of confidentiality 
 
Minutes from the DSMB meetings are available to anyone unable to attend the center DSMB. 
 
All toxicities encountered during the study will be evaluated on an ongoing basis according to 
the NCI Common Toxicity Criteria version 4.0. All study treatment associated adverse events 
that are serious, at least possibly related and unexpected will be reported to the IRB. Any 
modifications necessary to ensure subject safety and decisions to continue, or close the trial to 
accrual are also discussed during these meetings. If any literature becomes available which 
changes the risk/benefit ratio or suggests that conducting the trial is no longer ethical, the IRB 
will be notified in the form of an Unanticipated Problem submission and the study may be 
 
UPCI 12-048 44 02-15-2016 ter
minated. 
All study data reviewed and discussed during these meetings will be kept confidential. Any 
breach in subject confidentiality will be reported to the IRB in the form of an Unanticipated 
Problem submission. The summaries of these meetings are forwarded to the UPCI DSMC which 
also meets monthly following a designated format. 
For all research protocols, there will be a commitment to comply with the IRB’s policies for 
reporting unanticipated problems involving risk to subjects or others (including adverse events). 
DSMC progress reports, to include a summary of all serious adverse events and modifications, 
and approval will be submitted to the IRB at the time of renewal. 
Protocols with subjects in long-term (survival) follow-up or protocols in data analysis only, will 
be
 reviewed twice a year rather than monthly by the disease center DSMB. 
B
oth the UPCI DSMC as well as the individual disease center DSMB have the authority to 
suspend accrual or further investigate treatment on any trial based on information discussed at 
these meetings. 
All records related to this research study will be stored in a locked environment. Only the 
researchers affiliated with the research study and their staff will have access to the research 
records. 
14. AD VERSE EVENT REPORTING 
14.1 Adverse event definitions 
Adverse event (AE)  means any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related. 
Suspected adverse reaction  means any adverse event for which there is a reasonable possibility 
that the drug caused the adverse event. Suspected adverse reaction implies a lesser degree of 
certainty about causality than adverse reaction, which means any adverse event caused by a drug. 
Reasonable possibility , for the purpose of IND safety reporting, means there is evidence 
to suggest a causal relationship between the drug and the adverse event. 
Life-threatening adverse event or life-threatening suspected adverse reaction  is considered "life-
threatening" if, in the view of the sponsor-investigator, its occurrence places the patient or 
subject at immediate risk of death. It does not include an adverse event or suspected adverse 
reaction that, had it occurred in a more severe form, might have caused death. 
Serious adverse event or serious suspected adverse reaction  is considered "serious" if, in the 
view of the sponsor-investigator, it results in any of the following outcomes: death, a life-
threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a 
persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
 
UPCI 12-048 45 02-15-2016 func
tions, or a congenital anomaly/birth defect. 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the patient or subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such 
medic
al events include allergic bronchospasm requiring intensive treatment in the 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospitalization, or the development of drug dependency or drug abuse. 
Unexpected adverse event or unexpected suspected adverse reaction  is considered "unexpected" 
if it is not listed in the investigator brochure or is not listed at the specificity or severity that has 
been observed; or, if an investigator brochure is not required or available, is not consistent with 
the risk information described in the general investigational plan or elsewhere in the current 
application, as amended. 
For example, under this definition, hepatic necrosis would be unexpected (by virtue of 
greater severity) if the investigator brochure referred only to elevated hepatic enzymes or 
hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be 
unexpected (by virtue of greater specificity) if the investigator brochure listed only 
cerebral vascular accidents. “Unexpected,” as used in this definition, also refers to 
adverse events or suspected adverse reactions that are mentioned in the investigator 
brochure as occurring with a class of drugs or as anticipated from the pharmacological 
pr
operties of the drug, but are not specifically mentioned as occurring with the particular 
drug under investigation. 
14.2 Re cording/Reporting requirements 
14.2.1 Eliciting AE Information 
Research subjects will be routinely questioned about AEs at study visits. 
14.2.2 Recording Requirements 
All observed or volunteered adverse events (serious or non-serious) and abnormal test findings, 
regardless of study group or suspected causal relationship to the study drug(s) will be recorded in 
the subjec
ts’ case histories. For all adverse events, sufficient information will be pursued and/or 
obtained so as to permit 1) an adequate determination of the outcome of the event (i.e., whether 
the event should be classified as a serious adverse event) and; 2) an assessment of the casual 
re
lationship between the adverse event and the study drug(s). 
AEs or abnormal test findings felt to be associated with the investigational drug or study 
treatment(s) will be followed until the event (or its sequelae) or the abnormal test finding 
resolves or stabilizes at a level acceptable to the Sponsor-Investigator. 
 
UPCI 12-048 46 02-15-2016 14.2.2.1
 Abnormal Test Findings 
An abnormal test finding will be classified as an adverse event if one or more of the following 
criteria are met: 
 The test finding is accompanied by clinical symptoms. 
 The
 test finding necessitates additional diagnostic evaluation(s) or medical/surgical 
intervention; including significant additional concomitant drug treatment or other 
therapy. 
Note: simply repeating a test finding, in the absence of any of the other listed criteria, 
does not constitute an AE. 
 The test finding leads to a change in study drug dosing or discontinuation of subject 
participation in the clinical study. 
 The test finding is considered an AE by the Sponsor-Investigator of the IND application. 
 
14.2.2.2 Causality and severity assessment 
The Sponsor-Investigator of the IND application will promptly review documented adverse 
events and abnormal test findings to determine 1) if the abnormal test finding should be 
classified as an adverse event; 2) if there is a reasonable possibility that the adverse event was 
caused by the study drug(s); and 3) if the adverse event meets the criteria for a serious adverse 
event. 
If the Sponsor-Investigator’s final determination of causality is “unknown and of questionable 
relationship to the study drug(s)”, the adverse event will be classified as associated with the use 
of the study drug(s) for reporting purposes. If the Sponsor-Investigator’s final determination of 
causality is “unknown but not related to the study drug(s)”, this determination and the rationale 
for the determination will be documented in the respective subject’s case history. 
14.3 Re porting of Suspected Adverse Reactions 
All events meeting the definition of a serious adverse event should be recorded on a MedWatch 
3500A Form 
(http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM048334.pdf) or 
departmental SAE form. Copies should be sent to: 
1. I nvestigator-Sponsor 
2. crssafetysubmissions@upmc.edu 
3. Local Institutional Review Board per institutional reporting requirements 
 
In addition to completing appropriate patient demographic and suspect medication information, 
the report should include as applicable the following information that is available at the time of 
report within the Event Description (section 5) of the MedWatch 3500A form: 
• CTCAE term(s) and grade(s) 
• Current status of study drug 
 
UPCI 12-048 47 02-15-2016 • All interventions to address the AE (testing and result, treatment and response) 
• Hospitalization and/or discharge dates 
• Event relationship to study drug 
 
F
ollow-up reports: 
Additional information may be added to a previously submitted report by adding to the original 
MedWatch 3500A report and submitting it as follow-up or creating supplemental summary 
information and submitting it as follow-up with the original MedWatch 3500A form. 
14.4 Re view of Safety Information: Sponsor Responsibilities[1] 
The sponsor must promptly review all information relevant to the safety of the drug obtained or 
otherwise received by the sponsor from foreign or domestic sources, including information 
derived from any clinical or epidemiological investigations, animal or in vitro studies, reports in 
the scientific literature, and unpublished scientific papers, as well as reports from foreign 
regulatory authorities and reports of foreign commercial marketing experience for drugs that are 
not marketed in the United States. 
14.5 Re porting of Adverse Reactions to the FDA 
14.5.1 Written IND safety reports 
The Sponsor-Investigator will submit a written IND Safety Report (i.e., completed FDA Form 
3500 A) to the responsible new drug review division of the FDA for any observed or volunteered 
adverse event that is determined to be a serious and unexpected, suspected adverse reaction . 
Each IND Safety Report will be prominently labeled, “IND Safety Report”, and a copy will be 
provided to all participating investigators (if applicable) and sub-investigators. 
Written IND Safety Reports will be submitted to the FDA as soon as possible and, in no event, 
later than 15 calendar days following the Sponsor-Investigator’s receipt of the respective adverse 
e
vent information and determination that it meets the respective criteria for reporting. 
For each written IND Safety Report, the Sponsor-Investigator will identify all previously 
submitted IND Safety Reports that addressed a similar suspected adverse reaction experience and 
will provide an analysis of the significance of newly reported, suspected adverse reaction in light 
of the previous, similar report(s) or any other relevant information. 
Relevant follow-up information to an IND Safety Report will be submitted to the applicable 
review division of the FDA as soon as the information is available and will be identified as such 
(i.e., “Follow-up IND Safety Report”). 
If the results of the Sponsor-Investigator’s follow-up investigation show that an adverse event 
that was initially determined to not require a written IND Safety Report does, in fact, meet the 
requirements for reporting; the Sponsor-Investigator will submit a written IND Safety Report as 
                                                 
[1] 21 CFR Sec. 312.50 
 
UPCI 12-048 48 02-15-2016 soon a
s possible, but in no event later than 15 calendar days, after the determination was made. 
14.5.2 Telephoned IND safety reports – fatal or life-threatening suspected adverse reactions 
I
n addition to the subsequent submission of a written IND Safety Report (i.e., completed FDA 
Form 3500A), the Sponsor-Investigator will notify the responsible review division of the FDA 
by telephone or facsimile transmission of any unexpected, fatal or life-threatening suspected 
adverse reaction.  
The telephone or facsimile transmission of applicable IND Safety Reports will be made as soon 
as possible but in no event later than 7 calendar days after the Sponsor-Investigator’s receipt of 
the respective adverse event information and determination that it meets the respective criteria 
for reporting. 
14.6 Re porting adverse events to the responsible IRB 
In accordance with applicable policies of the University of Pittsburgh Institutional Review Board 
(IRB), the Sponsor-Investigator will report, to the IRB, any observed or volunteered adverse 
event that is determined to be 1) associated with the investigational drug or study treatment(s) ; 
2) serious ; and 3)  unexpected . Adve rse event reports will be submitted to the IRB in accordance 
with the respective IRB procedures. 
Applicable adverse events will be reported to the IRB as soon as possible and, in no event, later 
than 10 c
alendar days following the sponsor-investigator’s receipt of the respective information. 
Adverse events which are 1) associated with the investigational drug or study treatment(s) ; 2) 
fatal or life-threatening ; and 3) unexpected  will be reported to the IRB within 24 hours of the 
Sponsor-Investigator’s receipt of the respective information. 
Follow-up information to a reported adverse event will be submitted to the IRB as soon as the 
relevant information is available. If the results of the Sponsor-Investigator’s follow-up 
investigation show that an adverse event that was initially determined to not require reporting to 
the IRB does, in fact, meet the requirements for reporting; the Sponsor-Investigator will report 
the adverse event to the IRB as soon as possible, but in no event later than 10 calendar days, after 
the determination was made. 
15. WIT HDRAWAL OF SUBJECTS DUE TO ADVERSE EVENTS 
Therapy will be immediately discontinued for any grade 4 toxicity that becomes apparent or any 
toxicity outlined in the Regimen Limiting Toxicities Section 9.1.4. Study treatment will be 
re
initiated for any grade 3 (except toxicities outlined in the Regimen Limiting Toxicities) 
toxicity pending the reversal of such toxicity after withholding treatment. In the event of any 
adverse effect, appropriate medical treatment will be instituted and study treatment will be 
discontinued if the above toxicity remains. 
  
 
UPCI 12-048 49 02-15-2016 16. QUALIT Y CONTROL AND QUALITY ASSURANCE 
Independent monitoring of the clinical study for protocol and Guidelines on Good Clinical 
Practice compliance will be conducted periodically (i.e., at a minimum of annually) by qualified 
staff of the Education and Compliance Office – Human Subject Research, Research Conduct and 
C
ompliance Office, University of Pittsburgh. 
The Investigator (i.e., the study site principal investigator) and the University of Pittsburgh and 
University of Pittsburgh Medical Center will permit direct access of the study monitors and 
appropriate regulatory authorities to the study data and to the corresponding source data and 
documents to verify the accuracy of this data. 
17. DA TA HANDLING AND RECORD-KEEPING 
The Investigator (i.e., the study site principal investigator) will maintain records in accordance 
with Good Clinical Practice. 
The investigator will retain the specified records and reports for up to 2 years after the marketing 
application is approved for the investigational drug; or, if a marketing application is not 
submitted or approved for the investigational drug, until 2 years after investigations under the 
IND have been discontinued and the FDA so notified. 
18. E THICS 
18.1 Institutional Review Board (IRB) Approval 
The investigator (i.e., the study site principal investigator) will obtain, from the University of 
Pittsburgh Institutional Review Board (IRB), prospective approval of the clinical protocol and 
c
orresponding informed consent form(s); modifications to the clinical protocol and 
corresponding informed consent forms, and advertisements (i.e., directed at potential research 
subjects) for study recruitment, if applicable. 
The only circumstance in which a deviation from the current IRB-approved clinical 
protocol/consent form(s) may be initiated in the absence of prospective IRB approval is to 
eliminate an apparent immediate hazard to the research subject(s). In such circumstances, the 
investigator will promptly notify the University of Pittsburgh IRB of the deviation. 
The University of Pittsburgh IRB operates in compliance with FDA regulations at 21 CFR Parts 
50 and 21 CFR 56 , and in conformance with applicable International Conference on 
Harmonization (ICH) Guidelines on Good Clinical Practice. 
In the event that the University of Pittsburgh IRB requires, as a condition of approval, substantial 
changes to a clinical protocol submitted under an FDA-accepted IND application, or in the event 
of an sponsor’s decision to modify the previously accepted clinical protocol, the sponsor will 
submit (i.e., in advance of implementing the change) a Protocol Amendment to the IND 
describing any change that significantly affects the safety of subjects, the scope of the 
 
UPCI 12-048 50 02-15-2016 investi
gation, or the scientific quality of the study. Examples of protocol changes requiring the 
subm
ission of a Protocol Amendment include: 
 An y increase in drug dosage or duration of exposure of individual subjects to the 
investigational drug beyond that described in the current protocol, or any significant 
increase in the number of subjects under study. 
 An y significant change in the design of the protocol (such as the addition or deletion of a 
control group). 
 The  addition of a new test or procedure that is intended to improve monitoring for, or 
reduce the risk of, a side effect or AE; or the dropping of a test intended to monitor the 
safety of the investigational drug. 
18.2 E thical and Scientific Conduct of the Clinical Study 
The clinical study will be conducted in accordance with the current IRB-approved clinica l 
protocol; ICH Guidelines on Guidelines on Good Clinical Practice; and relevant policies, 
requirements, and regulations of the University of Pittsburgh IRB, University of Pittsburgh and 
University of Pittsburgh Medical Center, Commonwealth of Pennsylvania, and applicable federal 
agencies. 
18.3 S ubject Informed Consent 
The investigator (i.e., the study site principal investigator) will make certain that an appropriate 
informed consent process is in place to ensure that potential research subjects, or their authorized 
representatives, are fully informed about the nature and objectives of the clinical study, the 
potential risks and benefits of study participation, and their rights as research subjects. The 
investigator, or a sub-investigator(s) designated by the sponsor, will obtain the written, signed 
informed consent of each subject, or the subject’s authorized representative, prior to performing 
any study-specific procedures on the subject. The date and time that the subject, or the subject’s 
authorized representative, signs the informed consent form and a narrative of the issues discussed 
during the informed consent process will be documented in the subject’s case history. The 
investigator or sub-investigator will retain the original copy of the signed informed consent form, 
and a copy will be provided to the subject, or to the subject’s authorized representative. 
The investigator will make certain that appropriate processes and procedures are in place to 
ensure that ongoing questions and concerns of enrolled subjects are adequately addressed and 
that the subjects are informed of any new information that may affect their decision to continue 
participation in the clinical study. In the event of substantial changes to the clinical study or the 
risk-to-benefit ratio of study participation, the investigator will obtain the informed consent of 
enrolled subjects for continued participation in the clinical study. 
  
 
UPCI 12-048 51 02-15-2016 19. REF ERENCES 
1.   American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 
2011. 
2.   Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and 
cl
assification. J Clin Oncol.  2009; 27: 6199-6206. 
3.  
 Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with 
disseminated malignant melanoma: a phase III study. J Clin Oncol.  2004; 22: 1118-1125. 
4.  
 Bedikian AY, Millward M, Pehamberger H, et al.  Bcl-2 antisense (oblimersen sodium) plus 
dac
arbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin 
Oncol.  2006; 24: 4738-4745. 
5.  
 Schadendorf D, Ugurel S, Schuler-Thurner B, et al.  Dacarbazine (DTIC) versus vaccination with 
aut
ologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic 
melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol.  2006; 
17: 563-570. 
6.   
Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for 
pati
ents with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J 
Clin Oncol.  1999; 17: 2105-16 
7.   
Hodi FS, O'Day SJ, McDermott DF, et al.  Improved Survival with Ipilimumab in Patients with 
Me
tastic Melanoma. N Engl Med.  2010; 363: 711-723. 
8.  
 Flaherty KT, Puzanov I, Kim KB, et al.  Inhibition of Mutated, Activated BRAF in Metastatic 
Me
lanoma. N Engl J Med.  2010; 363: 809-819.  
9.   Curtin JA, Busam K, Pinkel D and Bastian BC. Somatic activation of KIT in distinct subtypes of 
melanoma. J Clin Oncol.  2006; 24: 4340-4346. 
10.  
 Antonescu CR, Busam KJ, FranconeTD, et al. L576P KIT mutation in anal melanomas correlates 
with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer  2007; 121: 
257-
264. 
11. 
 Went PT, Dirnhofer S, Bundi M, et al.  Prevalence of KIT expression in human tumors. J Cli n 
Oncol.  2004; 22: 4514-4522. 
12. 
 Willmore-Payne C, Layfield LJ and HoldenJA. c-KIT mutation analysis for diagnosis of 
g
astrointestinal stromal tumors in fine needle aspiration specimens. Cancer  2005; 105: 165-170. 
13. 
 Willmore-Payne C, Holden JA, Tripp S and Layfield LJ. Human malignant melanoma: detection 
of BRAF- and ckit- activating mutations by high-resolution amplicon melting curve analysis. 
Hum Pathol.  2005; 36: 486-493. 
14.  
 BMS-354825, Bristol-Myers Squibb Investigator Brochure, Version no. 5, Version date: 26- Jan-
2006. BMS Document Control No. 930003494. 
15.  Kluger HM, Dudek AZ, McCann C, et al.  A phase 2 trial of dasatinib in advanced melanoma. 
C
ancer . 2011; 117: 2202-2208. 
16. 
 Hersey P, Bastholt L, Chiarion-Sileni V, et al,  Small molecules and targeted therapies in distant 
metastatic disease. Ann Oncol.  2009;20 Suppl 6:  vi35- vi40. 
17.  Platsoucas CD. Human autologous tumor-specific T cells in malignant melanoma. Cancer 
Metastasis Rev . 1991; 10: 151-176.  
18.  Melief CJ and Kast WM. T-cell immunotherapy of cancer. Res Immunol.  1991; 142: 425-429.  
19. 
 Belldegrun A, Kasid A, Uppenkamp M, et al. Human tumor infiltrating lymphocytes. Analysis of 
lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol.  1989; 142: 
4520-
4526. 
20.  Weber J, Atkins M, Hwu P, et al. Immunotherapy Task Force of the NCI Investigational Drug 
Steering Committee. White paper on adoptive cell therapy for cancer with tumor-infiltrating 
lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res.  
2011; 17: 1664-1673. 
21.  
Hoffman DM, Gitlitz BJ, Belldegrun A and Figlin RA. Adoptive cellular therapy. Semin Oncol . 
2000; 27: 221-233. 
 
UPCI 12-048 52 02-15-2016 22. 
 van der Bruggen P, Traversari C, Chomez P, et al.  A gene encoding an antigen recognized by 
cy
tolytic T lymphocytes on a human melanoma. Science . 1991; 254: 1643-1647. 
23.  
Kawakami Y, Zakut R, Topalian SL, et al.  Shared human melanoma antigens. Recognition by 
t
umor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol.  1992; 148: 638-
643. 
24. 
 Nagorsen D and Thiel E. HLA typing demands for peptide-based anti-cancer vaccine. Cancer 
Immunol Immunother . 2008; 57: 1903-1910. 
25. 
 Keilholz U. Antigen-specific cancer vaccines. Recent Results Cancer Res. 2007; 176: 213-218. 
26.  Chi M and Dudek AZ. Vaccine therapy for metastatic melanoma: systematic review and meta-
analysis of clinical trials. Melanoma Res.  2011; 21: 165-174. 
27. 
 Vujanovic L and Butterfield LH. Melanoma cancer vaccines and anti-tumor T cell responses. J 
Cell Biochem.  2007;102:301-10. 
28. 
 Seliger B, Stoehr R, Handke D, et al.  Association of HLA class I antigen abnormalities with 
di
sease progression and early recurrence in prostate cancer. Cancer Immunol Immunother.  2010; 
59:
 529-540. 
29.  
Atkins D, Ferrone S, Schmahl GE, et al.  Down-regulation of HLA class I antigen processing 
m
olecules: an immune escape mechanism of renal cell carcinoma? J Urol.  2004; 171: 885-889. 
30. 
 Seliger B, Maeurer MJ and Ferrone S. Antigen-processing machinery breakdown and tumor 
growth. Immunol Today  2000; 21: 455-464.  
31. 
 Reiman JM, Kmieciak M, Manjili MH and Knutson KL. Tumor immunoediting and immuno-
sculpting pathways to cancer progression. Semin Cancer Biol.  2007; 17: 275-287. 
32. 
 Gajewski TF, Fallarino F, Ashikari A and Sherman M. Immunization of HLA- A2+ melanoma 
pat
ients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells 
plus recombinant human interleukin 12. Clin Cancer Res.  2001; 7: 895s-901s. 
33. 
 Hofmeister V, Schrama D and Becker JC. Anti-cancer therapies targeting the tumor stroma. 
Cancer Immunol Immunother . 2008; 57: 1-17. 
34. 
 Ahmed F, Steele JC, Herbert JM, et al.  Tumor stroma as a target in cancer. Curr Cancer Drug 
Targets.  2008; 8:  447-4 53. 
35.  Yu P, Rowley DA, Fu YX and Schreiber H. The role of stroma in immune recognition and 
destruction of well-established solid tumors. Curr Opin Immunol . 2006; 18: 226-231. 
36. 
 Singer CF, Gschwantler-Kaulich D, Fink-Retter A, et al.  Differential gene expression profile in 
br
east cancer-derived stromal fibroblasts. Breast Cancer Res Treat.  2008; 110: 273-281. 
37. 
 Ghilardi C, Chiorino G, Dossi R, et al.  Identification of novel vascular markers through gene 
expr
ession profiling of tumor-derived endothelium. BMC Genomics . 2008; 9: 201. 
38. 
 Hanson JA, Gillespie JW, Grover A, et al.  Gene promoter methylation in prostate tumor-
as
sociated stromal cells. J Natl Cancer Inst.  2006; 98: 255-261. 
39. 
 Yoshiura K, Nishishita T, Nakaoka T, et al.  Inhibition of B16 melanoma growth and metastasis in 
C
57BL mice by vaccination with a syngeneic endothelial cell line. J Exp Clin Cancer Res.  2009; 
28:
 13. 
40.  Okaji Y, Tsuno NH, Kitayama J, et al.  Vaccination with autologous endothelium inhibits 
angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci.  2004; 95: 85-90. 
41. 
 Lee SH, Mizutani N, Mizutani M, et al.  Endoglin (CD105) is a target for an oral DNA vaccine 
ag
ainst breast cancer. Cancer Immunol Immunother.  2006; 55: 1565-1574. 
42.  Maciag PC, Seavey MM, Pan ZK, et  al. Cancer immunotherapy targeting the high molecular 
w
eight melanoma-associated antigen protein results in a broad antitumor response and reduction 
of pericytes in the tumor vasculature. Cancer Res.  2008; 68: 8066-8075. 
43.  Kaplan CD, Krüger JA, Zhou H, et  al. A novel DNA vaccine encoding PDGFR  suppresses 
growth and dissemination of murine colon, lung and breast carcinoma. Vaccine . 2006; 24: 6994-
7002.
 
 
UPCI 12-048 53 02-15-2016 44.  Ishizaki H, Tsunoda T, Wada S, e t al. Inhibition of tumor growth with antiangiogenic cancer 
vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. 
Clin Cancer Res.  2006; 12: 5841-5849. 
45. 
 Luo Y, Markowitz D, Xiang R, et al. FLK-1-based minigene vaccines induce T cell-mediated 
suppr
ession of angiogenesis and tumor protective immunity in syngeneic BALB/c mice. Vaccine.  
2007; 25: 1409-1415. 
46.  
 Dong Y, Qian J, Ibrahim R, et al. Identification of H- 2Db-specific CD8+ T cell epitopes from 
mouse VEGFR2 that can inhibit angiogenesis and tumor growth. J Immunother.  2006; 29: 32-40. 
47. 
 Wada S, Tsunoda T, Baba T, et al.  Rationale for antiangiogenic cancer therapy with vaccination 
usi
ng epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer 
Res. 2005; 65: 4939-4946. 
48. 
  Zhao X, Bose A, Komita H, et al.  Intratumoral IL-12 gene therapy results in the cross-priming of 
T
c1 cells reactive against tumor-associated stromal antigens. Mol Ther.  2011; 19: 805-814. 
49.  
 Zhao X, Bose, A, Komita H, et al.  Vaccines targeting tumor-associated blood vessel antigens are 
protective/therapeutic in HLA-A2 transgenic mice. J. Immunol., in press,  2011. 
50. 
 Knutson KL and Disis ML. Tumor antigen-specific T helper cells in cancer immunity and 
immunotherapy. Cancer Immunol Immunother.  2005; 54: 721-728. 
51.  Mosmann TR and Sad S. The expanding universe of T cell subsets: Th1, Th2 and more. I mmunol 
Today. 1996; 17: 138-146. 
52.  Tatsumi T, Kierstead LS, Ranieri E, et al.  Disease-associated bias in T helper type 1 (Th1)/Th2 
CD4+ T cell responses against MAGE-6 in HLA-DRB1*0401+ patients with renal cell carcinoma 
or
 melanoma. J Exp Med.  2002; 196: 619-628. 
53. 
 Fourcade J, Sun Z, Kudela P, et al. Human tumor antigen-specific helper and regulatory T cells 
sha
re common epitope specificity but exhibit distinct T cell repertoire. J Immunol . 2010; 184: 
6709-6718. 
54.  Lüscher U, Filgueira L, Juretic A, et al.  The pattern of cytokine gene expression in freshly 
excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating 
lymphocytes. Int J Cancer . 1994; 57: 612-629. 
55.  thor Straten P, Becker JC, Guldberg P and Zeuthen J. In situ T cells in melanoma. Cancer 
Immunol Immunother. 1999; 48: 386-395. 
56. 
 Okada K, Komuta K, Hashimoto S, et al.  Frequency of apoptosis of tumor-infiltrating 
l
ymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with 
prognosis. Clin Cancer Res.  2000; 6: 3560-3564. 
57. 
 Hernandez-Chacon JA, Li Y, Wu RC, et al.  Costimulation through the CD137/4-1BB pathway 
pr
otects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and 
enhances antitumor effector function. J Immunother.  2011; 34: 236-250. 
58. 
 Wesa A, Kalinski P, Kirkwood JM, et al.  Polarized type-1 dendritic cells (DC1) producing high 
l
evels of IL-12 family members rescue patient TH1-type anti-melanoma CD4+ T cell responses in 
vitro. J Immunother . 2007; 30: 75-82. 
59.  
Finke JH, Rini B, Ireland J, et al.  Sunitinib reverses type-1 immune suppression and decreases T-
r
egulatory cells in renal cell carcinoma patients. Clin Cancer Res.  2008; 14: 6674-6682. 
60. 
 Ko JS, Zea AH, Rini BI, et al.  Sunitinib mediates reversal of myeloid-derived suppressor cell 
ac
cumulation in renal cell carcinoma patients. Clin Cancer Res.  2009; 15: 2148-2157. 
61.  
 Poschke I, Mougiakakos D, Hansson J, et al.  Immature immunosuppressive CD14+H LA-DR-/low 
cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-SIGN. Cancer Res.  
2010;
 70: 4335-4345. 
62.  Knol AC, Lemaître F, Pandolfino MC, et al. Absence of amplification of CD4+CD25hi regulatory 
T
 cells during in vitro  expansion of tumor-infiltrating lymphocytes in melanoma patients. Exp 
D
ermatol.  2008; 17: 436 -445. 
63.  Antony PA and Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and 
i
nterleukin-2. J Immunother.  2005; 28: 120-128. 
 
UPCI 12-048 54 02-15-2016 64. 
 Curiel TJ, Coukos G, Zou L, et al.  Specific recruitment of regulatory T cells in ovarian carcinoma 
f
osters immune privilege and predicts reduced survival. Nat Med.  2004; 10: 942-949. 
65.  Wolf D, Wolf AM, Rumpold H, et al.  The expression of the regulatory T cell-specific forkhead 
box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer 
Res. 2005; 11: 8326-8331. 
66. 
 Li X, Kostareli E, Suffner J, et al.  Efficient Treg depletion induces T-cell infiltration and 
r
ejection of large tumors. Eur J Immunol . 2010; 40: 3325-3335. 
67.  
Mahnke K, Schönfeld K, Fondel S, et al. Depletion of CD4+C D25+ human regulatory T cells in 
v
ivo: kinetics of Treg depletion and alterations in immune functions in vivo  and i n vitro . Int J 
Cancer.  2007; 120: 2723-2733. 
68. 
 Onizuka S, Tawara I, Shimizu J, et al.  Tumor rejection by in vivo administration of anti-CD25 
(interleukin-2Ra) monoclonal antibody. Cancer Res.  1999; 59: 3128-3133. 
69.  Dannull J, Su Z, Rizzieri D, et  al. Enhancement of vaccine-mediated antitumor immunity in 
ca
ncer patients after depletion of regulatory T cells. J Clin Invest . 2005; 115: 3623-3633. 
70. 
 Kusmartsev S and Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune 
evasion in cancer. Cancer Immunol Immunother.  2006; 55: 237-245. 
71.  Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. 
Nat Rev Immunol.  2004; 4: 941-952. 
72.  
 Zea AH, Rodriguez PC, Atkins MB, et al.  Arginase-producing myeloid suppressor cells in renal 
ce
ll carcinoma patients: a mechanism of tumor evasion. Cancer Res.  2005; 65: 3044-3048. 
73.  
 Gabrilovich DI, Velders MP, Sotomayor EM and Kast WM. Mechanism of immune dysfunction 
in ca
ncer mediated by immature Gr-1+ myeloid cells. J  Immunol.  2001; 166: 5398-5406. 
74. 
 Srivastava MK, Sinha P, Clements VK, et al.  Myeloid-derived suppressor cells inhibit T-cell 
ac
tivation by depleting cystine and cysteine. Cancer Res . 2010; 70: 68-77. 
75. 
 Zitvogel L, Mayordomo JI, Tjandrawan T, et al.  Therapy of murine tumors with tumor peptide-
pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated 
cytokines. J Exp Med.  1996; 183: 87-97.  
76.   Tuting T, Wilson CC, Martin DM, et  al. Autologous human monocyte-derived dendritic cells 
g
enetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in 
vitro : enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and 
IFN-. J Immunol. 1998; 160: 1139-1147.  
77.  Hiramoto JS, Tsung K, Bedolli M, et al.  Antitumor immunity induced by dendritic cell-based 
v
accination is dependent on interferon-  and interleukin-12. J Surg Res.  2004; 116: 64-69.  
78.   Steinman RM and Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of 
m
ice. I. Morphology, quantitation, tissue distribution. J Exp Med.  1973; 137: 1142-1162. 
79. 
 Steinman RM. Dendritic cells and immune-based therapies. Exp Hematol.  1996; 24:  859-862. 
80. 
 Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with 
synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med.  1995; 
1:
 1297-1302. 
81.  Nestle FO, Alijagic S, Gilliet M, et al.  Vaccination of melanoma patients with peptide- or tumor 
lysate-pulsed dendritic cells. Nat Med.  1998; 4: 328-332. 
82. 
 Nestle FO, Farkas A and Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. 
Curr Opin Immunol . 2005; 17: 163-169. 
83.  Banchereau J, Ueno H, Dhodapkar M, et al.  Immune and clinical outcomes in patients with stage 
IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and 
ac
tivated with type I interferon. J Immunother. 2005; 28: 505-516. 
84.  Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al.  Alpha-type-1 polarized dendritic cells: a 
nov
el immunization tool with optimized CTL-inducing activity. Cancer Res.  2004; 64: 5934-
5937.
 
 
UPCI 12-048 55 02-15-2016 85. 
 de Jong EC, Vieira PL, Kalinski P, et al.  Microbial compounds selectively induce Th1 cell-
pr
omoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals. J 
Immunol. 2002; 168: 1704-1709. 
86.  Vieira PL, de Jong EC, Wierenga EA, e t al. Development of Th1-inducing capacity in myeloid 
dendr
itic cells requires environmental instruction. J Immunol. 2000; 164: 4507-4512.  
87.  
 Kalinski P, Hilkens CM, Snijders A, et al.  IL- 12-deficient dendritic cells, generated in the 
presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T 
helper cells. J Immunol.  1997; 159: 28-35. 
88. 
Okada H, Kalinski P, Ueda R, et al.  Induction of CD8+ T-cell responses against novel glioma-
associated antigen peptides and clinical activity by vaccinations with -type 1 polarized dendritic 
cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in 
patients with recurrent malignant glioma. J Clin Oncol.  2011; 29: 330-336. 
89. 
Bose A, Taylor JL, Alber S, et al.  Sunitinib facilitates the activation and recruitment of 
t
herapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer.  2010; Dec 17 
[
Epub ahead of print]. 
90. Chang Q, Jorgensen C, Pawson T and Hedley DW. Effects of dasatinib on EphA2 receptor 
tyrosine kinase activity and downstream signaling in pancreatic cancer. Br J Cancer.  2008; 99: 
1074-
1082. 
91.  Carr KM, Bittner M and Trent JM. Gene-expression profiling in human cutaneous melanoma. 
Oncogene.  2003; 22: 3076-3080. 
92. 
 Udayakumar D, Zhang G, Ji Z, et al.  EphA2 is a critical oncogene in melanoma. O ncogene.  2011; 
Jun 13 [Epub ahead of print]. 
93.  Eggert AA, Schreurs MW, Boerman OC, et al.  Biodistribution and vaccine efficiency of murine 
dendr
itic cells are dependent on the route of administration. Cancer Res . 1999; 59: 3340-3345. 
94. 
 Linette GP, Zhang D, Hodi FS, et al.  Immunization using autologous dendritic cells pulsed with 
t
he melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. C lin 
Cancer Res.  2005; 11: 7692-7699. 
95. 
 Verdijk P, Aarntzen EH, Lesterhuis WJ, et al. Limited amounts of dendritic cells migrate into the 
T
-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin 
Cancer Res . 2009; 15: 2531-2540. 
96.  Lesterhuis WJ, de Vries IJ, Schreibelt G, et al. Route of administration modulates the induction 
of
 dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin 
Cancer Res.  2011; Jul 19 [Epub ahead of print]. 
97. 
 Castiglione F and Piccoli B. Cancer immunotherapy, mathematical modeling and optimal control. 
J Theor Biol . 2007; 247: 723 -732. 
98.  Draube A, Klein-González N, Mattheus S, et al. Dendritic cell based tumor vaccination in 
pr
ostate and renal cell cancer: a systematic review and meta-analysis. PLoS One . 2011; 6: 
e18801.  
99.  Schwaab T, Schwarzer A, Wolf B, et al.  Clinical and immunologic effects of intranodal 
aut
ologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN- 2a 
therapy in metastatic renal cell carcinoma patients. Clin Cancer Res.  2009; 15: 4986-4992. 
100.
 Ko JS, Rayman P, Ireland J, et al.  Direct and differential suppression of myeloid-derived 
suppr
essor cell subsets by sunitinib is compartmentally constrained. Cancer Res.  2010;70: 3526-
3536. 
 
101. Kawabe M, Mandic M, Taylor JL, et al.  Heat shock protein 90 inhibitor 17-dimethylamino 
et
hylamino- 17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific 
CD8+ T cells. C ancer Res.  2009; 69: 6995-7003. 
102. 
Wesa AK, Herrem CJ, Mandic M, et al.  Enhancement in specific CD8+ T cell recognition of 
EphA2+ tumors i n vitro  and in vivo  after treatment with ligand agonists . J Immunol.  2008; 181: 
7721-
7727.  
 
UPCI 12-048 56 02-15-2016 103.
 Yancovitz M, Yoon J, Mikhail M, et al. Detection of mutant BRAF alleles in the plasma of 
pat
ients with metastatic melanoma. J Mol Diagn. 2007; 9: 178-183. 
104. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: 
revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247. 
 
 
 
UPCI 12-048 57 02-15-2016 A
PPENDIX A 
 
Performance Status Criteria 
 
ECOG Performance Status Scale  Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
0 Normal activity . Fully active, able to 
carry on all pre -disease performance 
without restriction.  100 Normal, no complaints, no evidence of 
disease.  
90 Able to carry on normal activity; minor 
signs or symptoms of disease.  
1 Symptoms, but ambulatory . 
Restricted in physically strenuous 
activity, but ambulatory and able to 
carry out work of a light or sedentary 
nature ( e.g., light housework, office 
work).  80 Normal activity with effort; some signs 
or symptoms of disease.  
70 Cares for self, unable to carry on 
normal activity or to do active work.  
2 In bed <50% of the time . Ambulatory 
and capable of all self -care, but 
unable to carry out any work 
activities . Up and about more than 
50% of waking hours.  60 Requires occasional assistance, but is 
able to care for most of his/her needs.  
50 Requires considerable assistance and 
frequent medical care.  
3 In bed >50% of the time . Capable of 
only limited self -care, confined to bed 
or chair more than 50% of waking 
hours.  40 Disabled, requires special care and 
assistance.  
30 Severely disabled, hospitalization 
indicated . Death not imminent.  
4 100% bedridden . Completely 
disabled . Cannot carry on any self -
care. Totally confined to bed or chair.  20 Very sick, hospitalization indicated. 
Death not imminent.  
10 Moribund, fatal processes progressing 
rapidly.  
5 Dead.  0 Dead.  
 